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ABSTRACT 
BACKGROUND 
Many economic evaluations of human papillomavirus (HPV) vaccination consider multiple disease 
outcomes in addition to cervical cancer, including anogenital warts, recurrent respiratory 
papillomatosis, and anal, oropharyngeal, penile, vulvar and vaginal cancers. However, these 
evaluations mostly derive cost and utility parameters for these outcomes from single studies or 
informal rapid literature reviews. 
METHODS 
We conducted a systematic review of articles up to June 2016 to identify costs and utility estimates 
admissible for an economic evaluation from a single-payer health care provider’s perspective. Meta-
analysis was performed for studies that used same utility elicitation tools for similar diseases. Costs 
were adjusted to 2016/17 US dollars. 
RESULTS 
Sixty one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10,742 initial records. 
Cost per case ranges were US$124–US$883 (anogenital warts), US$6,912–US$52,579 (head and neck 
cancers), US$12,936–US$51,571 (anal cancer), US$17,524–34,258 (vaginal cancer), US$14,686–
28,502 (vulvar cancer), and US$9,975–27,629 (penile cancer). Total cost for 14 adult RRP patients 
was US$137,601 (1 paper). 
Utility per warts episode ranged from 0.651–1 (12 papers, various utility elicitation methods), with 
pooled mean EQ-5D and EQ-VAS of 0.86 (95% CI 0.85–0.87) and 0.74 (95% CI 0.74–0.75), 
respectively. Fifteen papers reported utilities in head and neck cancers, with range across studies of 
0.29 to 0.94. Mean utility reported ranged from 0.5 to 0.65 (anal cancer; range across studies), 0.59 
(0.54–0.64) (vaginal cancer), 0.65 (0.60–0.70) (vulvar cancer), and 0.79 (0.74–0.84) (penile cancer). 
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CONCLUSIONS 
Differences in values reported from each paper reflect variations in cancer site, disease stages, study 
population, treatment modality/setting, and utility elicitation methods used. As patient 
management changes over time, corresponding effects on both costs and utility need to be 
considered to ensure health economic assumptions are up-to-date and closely reflect the case-mix 
of patients. 
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KEY MESSAGES 
• This systematic review identified 61 papers (35 costs; 24 utilities; 2 costs and utilities) reporting 
economic parameters for HPV-related non-cervical diseases. 
• Differences in cost and utility estimates arise from study population, disease stage, cancer type, 
treatment strategies and country perspective taken. 
• Authors of economic evaluations need to consider economic parameter assumptions to ensure 
they accurately reflect the timing and perspective of the population considered. 
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INTRODUCTION 
Almost a hundred economic evaluations of human papillomavirus (HPV) vaccination had been 
published by June 2016[1–3]. Initially most of these analyses focused on the health and economic 
benefits of HPV vaccination in preventing cervical cancer and its precursors, since these were the 
only cancer outcomes listed in the initial licensure indication for the first two licensed HPV vaccines 
(the bivalent vaccine Cervarix and the quadrivalent vaccine Gardasil)[4,5]. More recently, evidence 
has emerged of other diseases that are potentially HPV vaccine-preventable, including recurrent 
respiratory papillomatoses (RRP) and non-cervical cancers such as vulvar, vaginal, anal, penile, and 
head and neck cancers[6,7]. Although attributable risk of HPV in each of these non-cervical cancers 
varies[7], these outcomes are important to incorporate into cost of illness studies of HPV-related 
diseases and economic evaluation of HPV vaccination for two reasons: (i) they give a comprehensive 
picture of the (direct and indirect) benefits of introducing HPV vaccination, and (ii) they are the key 
drivers of comparative evaluations of different strategies for vaccination, such as gender-neutral 
compared with female-only vaccination and the choice between nonavalent, quadrivalent and 
bivalent vaccination. 
Economic evaluations require input parameters in terms of the costs and disutilities (measured in 
units such as quality adjusted life years or QALYs) for different disease outcomes. To our knowledge, 
most published economic evaluations to date have relied on data from the authors’ own knowledge 
or from informal rapid reviews of the literature. Additionally, there exist a number of systematic 
reviews (without quantitative evidence synthesis) conducted before 2013 covering quality of life for 
specific diseases such as anogenital warts[8] and head and neck cancers[8–11] but none known of in 
more recent years covering a wider range of non-cervical HPV-related diseases on both costs and 
utilities. This gap in the literature may have led to bias in published economic evaluations because 
they may have failed to consider the entirety of the literature in their parameter estimates. 
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To address this shortcoming, we have conducted a systematic review to compile and summarise 
costs and quality of life (utility) estimates relevant to HPV-related diseases apart from cervical 
cancer. We have selected studies that would be admissible for an economic evaluation from the 
perspective of a single-payer health care provider such as the reference case used by the National 
Institute for Health and Care Excellence (NICE) in the United Kingdom[12].  
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METHODS 
Search Methods 
A search of the databases Ovid Medline, Embase, Cinahl, Scopus and NHS Economic Evaluations 
Database was performed in June 2016.  The search strategy combined terms for HPV-related 
diseases with health economics terms. HPV-related disease terms included both free text and, where 
available, subject headings for the following (ICD-10 codes in parentheses): anogenital warts – AGW 
(A63.0), recurrent respiratory papillomatosis – RRP (D14), cervical cancer (C53), vulvar cancer (C51), 
vaginal cancer (C52), anal cancer (C21), penile cancer (C60), oropharyngeal cancer (C09 and C10), 
oral cavity cancer (C01 to C05) – including cancer of the tonsil, laryngeal cancer (C32), and head and 
neck cancer as a general term included for completeness, recognising that not all head and neck 
cancers are HPV-attributed. Health economics terms included terms for health utilities/disutilities, 
costs, quality of life, quality of life instruments (e.g. EQ-5D) and measurement methods such as time-
trade off (TTO) and standard gamble (SG).  Results were limited to peer-reviewed full research 
articles in the English language only. Inclusion criteria covered all papers on HPV-related diseases 
costs and/or disutilities from high-income countries as defined by the Organisation for Economic 
Cooperation and Development, stated in Appendix 1[13]. 
Details of the full search strategies used are provided in Appendix 1. 
Result Screening 
Screening was undertaken from September to December 2016.  The initial 10,742 articles identified 
were independently single screened based on titles and abstracts to identify potentially relevant 
papers (KJO, MC, CP). Allocation decisions at this stage were done leniently, with titles that were 
uncertain marked for a further round of screening. The 2,785 references selected were entered into 
another round of single screening (KJO, MC, CP), whereby the results were reconsidered and 
categorised by type (cost or disutility) and disease area. 
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Although the objective of this systematic review focused on non-cervical diseases, for completeness, 
the search strategy and first two stages of single screening included cervical precancer/cancer. 
Selected titles for cervical precancer/cancer can be made available to interested researchers. 
Selection criteria 
Once titles from the second single screen had been identified, full-text papers were proportionately 
distributed to each reviewer (KJO, MC, CP) for the final round of paper selection and data extraction. 
For HPV-related disease management costs we included only papers that took the perspective of a 
health care provider from a country with universal healthcare system (either Bismarck-type or 
Beveridge-type). For utility estimates, any paper that reported on quality of life loss that was 
reported on a scale from 0 to 1 and measured using either an indirect generic utility elicitation tool 
such as the EuroQol EQ-5D, or one of the primary/direct methods such as time-trade off or standard 
gamble were included. These criteria ensured that selected studies would be admissible for 
economic evaluations in most single-payer health care jurisdictions (eg. the NICE reference 
case[12]). 
Data extraction 
A standard form to collect the data was created. Relevant data extracted from the papers are 
described in Appendix 2. 
Data extraction was done by one reviewer and checked by a second reviewer, with discrepancies 
resolved through discussion. 
Data synthesis 
A descriptive comparison of data extracted from different papers was made. Costs were adjusted to 
2016/17 US dollars using the hospital and community health services inflation indices, with foreign 
currencies converted to US dollars using historical Bank of England average exchange rates for a 
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reported year[14,15]. Quality of life values were presented separately for utility score and duration 
of disutility, if reported in a paper. 
Meta-analyses were conducted for AGW utility estimates for papers whereby utility estimates were 
generated using standard utility elicitation instruments, such that outcomes measured were 
comparable. Meta-analyses were not conducted for utility weights of non-AGW outcomes nor were 
they conducted for any cost estimates, given higher heterogeneity in how costs were measured and 
the specific disease type and stages considered. 
Software 
References were collected in EndNote and transferred to Eppi-Reviewer 4 software (Thomas J, 
Brunton J, Graziosi S, 2010) for screening. Final papers were captured in Mendeley Version 1.15.3. 
Data extraction was collated in Microsoft Excel 2010. Meta-analysis was conducted in STATA13. 
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RESULTS 
The initial search strategy identified 10,742 records after deduplication. Screening based on titles 
and abstracts reduced these to 729 full-text papers that were reviewed. Of these, 61 papers were 
selected. A PRISMA flow diagram is presented in  
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FIGURE LEGEND 
Figure 1. 
 
Costs 
A total of 37 papers reported non-cervical HPV-related disease management costs[16–52], about 
half of which reported costs for AGWs[16–35]. Four papers reported costs for more than one 
disease[26,30,36,37]. Management costs from studies differed by country, disease stages or 
management settings used, and data collection method. 
Figure 2 (Panel A) presents a summary of the various cost per case estimates, where presented, for 
AGWs. Estimated cost per case of AGW ranged from US$124 per case in a patient seen for care in 
Canada[25] to US$883 per case in Spain[34]. AGW management costs were derived from 
information collected from case note reviews (13 papers)[18–22,25,26,28,29,31–34], expert opinion 
(3 papers)[16,24,35], surveillance data (3 papers) [17,23,27] or the literature (1 paper) [30]. 
Cost per case reported for the various cancers is presented in Figure 2 (Panel B). Six papers reported 
management cost for anal cancers[30,36–40], but half of these were annual treatment 
costs[37,39,40] not cost per case. Cost per anal cancer case ranged from US$12,936 (Italy[30]) to 
US$51,571 (Denmark[36]). Twelve reported head and neck cancer treatment costs and differed 
depending on cancer site and stage[30,37,41–50], with costs ranging from US$6,912 (Laryngeal 
cancer, T1 carcinoma, the Netherlands[48]) to US$52,579 (weighted average costs for cancers of the 
oral cavity, larynx or oropharynx, the Netherlands[45]). There were four papers each that reported 
cost for vaginal[26,30,36,37], vulvar[26,30,36,37], and penile[30,36,37,51] cancers, with cost ranges 
of US$17,524–34,258, US$14,686–28,502, and US$9,975–27,629, respectively. Six papers only 
presented total spend and/or annual spend for the non-cervical cancers[37,39,40,42,44,52], detailed 
findings are reported in Appendix 2. 
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One paper reported on total treatment cost covering 14 adult patients seen for RRP care at a clinic in 
Glasgow, Scotland, between January 2013 to April 2014 was reported at US$137,601[52]. 
 
Utilities 
A total of 25 papers on health-related quality of life were identified (full reference list in Appendix 
2)[19,20,53–75]. Two of these covered multiple diseases[53,75]. Fifteen papers covered head and 
neck cancers, including oral and laryngeal cancers[53,62–75], whilst another 12 papers reported on 
quality of life for AGWs[19,20,53–61,76]. 
 
Utility per case of AGW ranged from 0.651–1, depending on the method of utility elicitation used. 
Utility values were generally higher when measured using EQ-5D, compared with Visual Analog Scale 
(VAS), TTO, or SG methods used within a single study. Full details of study background and findings 
are presented in Appendix 2. Meta-analyses of EQ-5D and EQ-VAS, from nine papers each, found 
high heterogeneity (I-squared >90%) in the utility values reported (Figure 3). Pooled mean EQ-5D 
and EQ-VAS were 0.86 (95% CI 0.85-0.87) and 0.74 (95% CI 0.74-0.75), respectively. 
Methods used to elicit utility for HPV-related cancers included EQ-5D, EQ-VAS, HUI3 (Health Utility 
Index Mark 3), TTO, SG, SF-36 (Short-Form 36), SF-6D (Short-Form Six-Dimension), and 15D. Utility 
estimates for head and neck cancers differed depending on the utility elicitation method used to 
generate utility scores, cancer site, patient age, the disease stage at point of completion of the 
quality of life questionnaire, and treatment modality. We present summary study details and key 
utility output presented in each of these 15 papers on quality of life for HPV-related cancers in Table 
1 with further details in Appendix 2. 
  
Page 11 of 90
https://mc.manuscriptcentral.com/sti
Sexually Transmitted Infections
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
12 
 
TABLE 
Table 1 Summary utility measurement and value ranges for HPV-related non-
cervical cancers 
No. Author, 
year 
Cancer type; 
notes 
Country n Utility elicitation instrument used; 
mean (unless otherwise specified) 
values and/or ranges reported 
1 Aro, 
2016[62] 
Head and neck Finland 214 15D; 0.872 
2 Govers, 
2016[63] 
Oral; mean 
years after 
treatment 
range 1.9 (SD 
1.4, range 0.4-
4.1) to 5.2 (SD 
3.2, range 0.4-
11.0) 
The 
Netherlands 
174 EQ5D; range 0.794 (SE 0.04) to 0.863 
(SE 0.05) 
EQVAS; range 69.7 (SE 3.7) to 79.6 (SE 
4.8) 
3 Pickard, 
2016[64] 
Head and neck US 50 EQ5D; 0.828 
EQVAS; 60.8 
4 Rettig, 
2016[65] 
Head and neck; 
sites include 
larynx, oral 
cavity, 
oropharynx, 
hypopharynx, 
nasopharynx, 
US 1653 SF6D; range 83.7 (95% CI 82.0, 85.4) to 
88.0 (95% CI 86.2, 89.7) 
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and nasal 
cavity/paranasal 
sinuses 
5 Kent, 
2015[66] 
Oral cavity and 
pharynx 
US  SF6D; 0.69 (95% CI 0.68, 0.70) 
6 Loimu, 
2015[67] 
Head and neck Finland 64 15D; range 0.829 (0.12) to 0.886 (0.10) 
7 Noel, 
2015[68] 
Head and neck Canada  EQ5D; 0.82 (SD 0.18, range -0.07-1.0) 
EQVAS; 0.76 (SD 0.19, range 0.2-1.0) 
SG; 0.91 (SD 0.17, range 0.2-1.0) 
TTO; 0.94 (SD 0.14, range 0.3-1.0) 
HUI3; 0.75 (SD 0.25, range -0.06-1.0) 
8 Pottel, 
2015[69] 
Head and neck Belgium 81 EQ5D; median (Q1, Q3) range 0.29 
(0.0, 0.76) to 0.66 (0.55, 0.76) 
9 Lango, 
2014[70] 
Head and neck US 159 EQ5D; median 85 (IQR: 70-90) 
10 Nijdam, 
2008[71] 
Head and neck The 
Netherlands 
119 EQ5D; median 75 
11 Rogers, 
2006[72] 
Head and neck UK  EQ5D; 0.75 (SE 0.02; range -0.18 - 1.0) 
EQVAS; 74 (SE 1) 
12 Ringash, 
2000[73] 
Laryngeal Canada 84 TTO; 0.878 (SD 0.174; range 0.25 - 1) 
13 Downer, 
1997[74] 
Oral UK 100 SG; range 0.68 (SD 0.33) to 0.88 (SD 
0.20) 
14 Marcellusi, Anal  Italy 26 EQ5D; 0.6 (SD 0.3) 
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2015[53] TTO; range 0.5 (SD 0.26; 95% CI 0.4-
0.61) to 0.52 (SD 0.25; 95% CI 0.36-
0.67) 
Head and neck; 
squamous cell 
carcinoma 
Italy 79 EQ5D; 0.8 (SD 0.2) 
TTO; range 0.69 (SD 0.3; 95% CI 0.62-
0.75) to 0.59 (SD 0.3; 95% CI 0.46-0.72) 
15 Conway, 
2012[75] 
Anal Australia 95 SG; 0.57 (95% CI 0.52 - 0.62); median 
0.65 (IQR 0.45 - 0.75) 
Oropharyngeal Australia 99 SG; 0.58 (95% CI 0.53 - 0.63); median 
0.65 (IQR 0.45 - 0.75) 
Vaginal  Australia 98 SG; 0.59 (0.54 - 0.64); median 0.65 (IQR 
0.45 - 0.75) 
Vulvar  Australia 98 SG; 0.65 (0.60 - 0.70); median 0.65 (IQR 
0.45 - 0.85) 
Penile  Australia 97 SG; 0.79 (0.74 - 0.84); median 0.85 (IQR 
0.65 - 1.0) 
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DISCUSSION 
Statement of principal findings 
This systematic review provides an updated and comprehensive summary of the cost and utility 
evidence for non-cervical HPV-related diseases that can be used in economic evaluations conducted 
from the perspective of a national health care provider. There appeared to be high heterogeneity in 
the papers identified, in terms of disease stages, population studied, treatment modality and setting, 
as well as utility elicitation methods used. The EuroQoL EQ-5D or EQ-VAS was commonly used in 
AGWs and in at least half of the non-cervical cancers studies. 
Whilst the evidence in terms of both costs and utility values appear to be abundant for AGWs, it is 
less so for other cancers. This may reflect the fact that protection against AGWs is one of the main 
differentiating factors between the two competing HPV vaccines (quadrivalent and bivalent) on the 
market until licensure of the nonavalent vaccine in 2015, with several published economic 
evaluations focusing on the difference in cost-effectiveness between the two vaccines[77]. 
Strengths and weaknesses of the study 
Many papers did not report a single overall cost or utility estimate for a disease episode. Instead, 
they reported cost or utility values at different stages of the disease, which means that to obtain a 
single overall figure over entire disease episode, further details about patient case mix and changes 
in utility over time are needed. This includes a combination of treatment received at different stages 
of disease. For example, Kim et al., 2011, reported post-operative management cost for a selective 
group of head and neck cancer patients who had received surgical resection[43]. 
In addition, treatment modalities are likely to change over time, with corresponding effects on both 
treatment costs and quality of life (due to changes in recovery time and patient experience). This 
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means that applying the same methodology to the same group of patients but managed differently 
will likely return different costs and utility estimates. 
The NICE-recommended utility elicitation method is EQ-5D completed by patients and scored using 
population norms. This type of evidence is not always available. When alternative utility elicitation 
methods are used, such as direct utility elicitation methods, their score can be quite different, as 
demonstrated by Noel et al., 2015[68]. In their study, patients with upper aerodigestive tract cancer 
completed five direct/indirect utility measures (EQ-5D, VAS, HUI3, standard gamble, and time trade-
off). The authors found that direct utility elicitation methods (SG and TTO) returned higher utility 
scores, possibly due to patients being more risk-averse. When the SG method was used in another 
study (Conway et al., 2012[75]) completed by general population, the utility score for oropharyngeal 
cancers was lower than head and neck cancers scored using SG in Noel et al., 2015[68], although this 
could be due to the scenario descriptions used. 
Meaning of the study: possible mechanisms and implications for clinicians or 
policymakers 
This systematic review highlights the importance of understanding the data source used in economic 
evaluation, ensuring that health economic assumptions are up-to-date and closely reflect the case-
mix of patients considered in the analysis. 
Unanswered questions and future research 
During the paper screening and evaluation of eligibility stage, many papers on head and neck 
cancers were identified but they often used SF-36 generic utility measures and reported two 
summary scores covering physical and mental domains separately. Only four studies[56,59,65,66] 
reported a single summary score and were included. To be most applicable to economic evaluations, 
mapping exercises are needed to convert SF-36 values to single SF-6D scores specific to a country's 
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population. Future analyses could consider extracting findings from relevant papers and converting 
to SF-6D scores, especially for diseases with insufficient utility estimates evidence. 
Future research can also focus on identifying the duration of disutility to be applied to a disease, 
since quality of life changes over time, and is an important component of the QALY calculations. 
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FIGURE LEGEND 
Figure 1 PRISMA flow diagram 
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Figure 2 Disease management costs reported in selected papers. Panel A 
outlines costs reported for anogenital warts (AGWs). Panel B contains an 
extraction of non-cervical cancer management costs; Panel A: Cost per case 
of AGWs management as reported in the relevant papers; Note that overall 
cost per patient is presented where this information is available, otherwise, 
cost per patient broken down by e.g. gender or new/recurrences presented 
and these are specified; Herse et al., 2011 not included as they presented 
minimum and maximum total cost of all patients, not per patient; Cost per 
patient for resistant cases reported in Hillemanns et al., 2008 not presented on 
this figure; Panel B: Cost per case of cancer management; Figure only 
presents cost per patient for their cancer management, excluding where only 
annual costs were reported or where total cost to the health care system was 
reported but not per patient cost; Note: H&N=Head and neck; Preuss, 2007, 
minimum and maximum costs reported for oropharyngeal carcinomas 
treatment with surgery and postoperative radio(chemo)therapy.  
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Figure 3 Forest plots of pooled mean (95% CI) of studies reporting AGW EQ-5D 
(Panel A) and EQ-VAS (Panel B) utility estimates; Panel A: Pooled AGW EQ-5D 
utility estimates; Panel B: Pooled AGW EQ-VAS utility estimates. Note: utility 
estimates for different subgroups within Vriend, 2014[54] and Drolet, 2011[56] 
were pooled together and the combined mean and 95% CI were subsequently 
added to utility estimates from the other studies to generate an overall pooled 
mean and 95% CI. 
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Figure 1 PRISMA flow diagram  
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Figure 2 Disease management costs reported in selected papers. Panel A outlines costs reported for 
anogenital warts (AGWs). Panel B contains an extraction of non-cervical cancer management costs; Panel A: 
Cost per case of AGWs management as reported in the relevant papers; Note that overall cost per patient is 
presented where this information is available, otherwise, cost per patient broken down by e.g. gender or 
new/recurrences presented and these are specified; Herse et al., 2011 not included as they presented 
minimum and maximum total cost of all patients, not per patient; Cost per patient for resistant cases 
reported in Hillemanns et al., 2008 not presented on this figure; Panel B: Cost per case of cancer 
management; Figure only presents cost per patient for their cancer management, excluding where only 
annual costs were reported or where total cost to the health care system was reported but not per patient 
cost; Note: H&N=Head and neck; Preuss, 2007, minimum and maximum costs reported for oropharyngeal 
carcinomas treatment with surgery and postoperative radio(chemo)therapy.  
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Figure 3 Forest plots of pooled mean (95% CI) of studies reporting AGW EQ-5D (Panel A) and EQ-VAS 
(Panel B) utility estimates; Panel A: Pooled AGW EQ-5D utility estimates; Panel B: Pooled AGW EQ-VAS 
utility estimates. Note: utility estimates for different subgroups within Vriend, 2014[54] and Drolet, 
2011[56] were pooled together and the combined mean and 95% CI were subsequently added to utility 
estimates from the other studies to generate an overall pooled mean and 95% CI.  
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Appendix 1 
 
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid 
MEDLINE(R) 1946 to Present 
1 Condylomata Acuminata/    
2 (anogenital adj3 (wart* or polyp*)).ab,ti.    
3 (genital adj3 (wart* or polyp*)).ab,ti.    
4 ((anal or anus) adj3 (wart* or polyp*)).ab,ti.    
5 "condyloma* acuminat*".ab,ti.    
6 "recurrent respiratory papilloma*".ab,ti.    
7 RRP.ab,ti.    
8 Uterine Cervical Neoplasms/    
9 
(cervi* adj5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)).ab,ti. 
   
10 Vulvar Neoplasms/    
11 
(vulva* adj5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)).ab,ti. 
   
12 Vaginal Neoplasms/    
13 
(vagina* adj5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)).ab,ti. 
   
14 exp Anus Neoplasms/    
15 
((anal or anus) adj5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)).ab,ti. 
   
16 Penile Neoplasms/    
17 
((penile or penis) adj5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)).ab,ti. 
   
18 exp "Head and Neck Neoplasms"/    
19 
((oral* or intra-oral* or intraoral* or "intra oral*" or gingiva* or orophary* or mouth* or tongue* or tonsil* or 
cheek* or gum* or palatal* or palate* or "head and neck") adj5 (cancer* or neoplasm* or malignan* or 
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tumor* or tumour* or carcinom* or adenocarcinom*)).ab,ti. 
20 
((laryn* or pharyn* or vocal cord* or cordal or glott* or throat or voice box or subglott* or supraglott*) adj5 
(cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or adenocarcinom*)).ab,ti. 
   
21 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20    
22 Quality-Adjusted Life Years/    
23 Quality of Life/    
24 "quality of life".ti,kw,kf.    
25 (health utilit* or utilit* measure* or utilit* instrument*).ab,ti.    
26 "Disutilit*".ab,ti.    
27 (QALY* or DALY*).ab,ti.    
28 (Quality adjusted life year* or Disability adjusted life year*).ab,ti.    
29 (EQ-5D or EQ5D or EQ-5D-3L or EQ-5D-5L).ab,ti.    
30 (SF-12 or SF12).ab,ti.    
31 (SF-6D or SF6D).ab,ti.    
32 (HUI or "H.U.I").ab,ti.    
33 (SF-36 or SF36).ab,ti.    
34 time trade off.ab,ti.    
35 standard gamble.ab,ti.    
36 cost*.ti,ab,kw,kf.    
37 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36    
38 
(America* or Australia* or Austria* or Belgium or Belgian or Britain or British or Canad* or Chile or Chilean 
or Czech or Denmark or Danish or Estonia* or Finland or Finnish or France or French or German* or 
Hungary or Hungarian or Iceland* or Ireland or Irish or Italy or Italian or Japan* or Korea* or Luxembourg 
or Mexico or Mexican or Netherlands or Dutch or New Zealand* or Norway or Norwegian or Poland or 
Polish or Portug* or Slovak* or Slovenia* or Spain or Spanish or Sweden or Swedish or Switzerland or 
Swiss or Turkey or Turkish or United Kingdom or United States).ab,hw,in,kf,ti. 
   
39 exp Great Britain/ or Europe/    
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40 (national health service* or nhs*).ab,hw,in,kf,ti.    
41 
(english not ((published or publication* or translat* or written or language* or speak* or literature or 
citation*) adj5 english)).ti,ab. 
   
42 
(gb or "g.b." or britain* or british or uk or "u.k." or united kingdom* or england* or ireland* or irish* or 
scotland* or scottish* or wales or welsh).ab,hw,in,kf,ti. 
   
43 
(bath or "bath's" or birmingham or "birmingham's" or bradford or "bradford's" or brighton or "brighton's" or 
bristol or "bristol's" or carlisle* or "carlisle's" or cambridge or "cambridge's" or canterbury or "canterbury's" 
or chelmsford or "chelmsford's" or chester or "chester's" or chichester or "chichester's" or coventry or 
"coventry's" or derby or "derby's" or durham or "durham's" or ely or "ely's" or exeter or "exeter's" or 
gloucester or "gloucester's" or hereford or "hereford's" or hull or "hull's" or lancaster or "lancaster's" or 
leeds* or leicester or "leicester's" or lincoln or "lincoln's" or liverpool or "liverpool's" or london or "london's" 
or manchester or "manchester's" or newcastle or "newcastle's" or norwich or "norwich's" or nottingham or 
"nottingham's" or oxford or "oxford's" or peterborough or "peterborough's" or plymouth or "plymouth's" or 
portsmouth or "portsmouth's" or preston or "preston's" or ripon or "ripon's" or salford or "salford's" or 
salisbury or "salisbury's" or sheffield or "sheffield's" or southampton or "southampton's" or st albans or 
stoke or "stoke's" or sunderland or "sunderland's" or truro or "truro's" or wakefield or "wakefield's" or wells 
or westminster or "westminster's" or winchester or "winchester's" or wolverhampton or "wolverhampton's" 
or worcester or "worcester's" or york or "york's").ab,hw,in,kf,ti. 
   
44 
(bangor or "bangor's" or cardiff or "cardiff's" or newport or "newport's" or st asaph or "st asaph's" or st 
davids or swansea or "swansea's").ab,hw,in,kf,ti. 
   
45 
(aberdeen or "aberdeen's" or dundee or "dundee's" or edinburgh or "edinburgh's" or glasgow or 
"glasgow's" or inverness or perth or stirling or "stirling's").ab,hw,in,kf,ti. 
   
46 
(armagh or "armagh's" or belfast or "belfast's" or lisburn or "lisburn's" or londonderry or "londonderry's" or 
derry or "derry's" or newry or "newry's").ab,hw,in,kf,ti. 
   
47 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46    
48 21 and 37 and 47    
49 limit 48 to english language    
50 (case reports or clinical conference).pt.    
51 49 not 50    
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Ovid Embase 1974 to 2016 July 05 
1 Condyloma Acuminatum/    
2 (anogenital adj3 (wart* or polyp*)).ti,ab.    
3 (genital adj3 (wart* or polyp*)).ti,ab.    
4 ((anal or anus) adj3 (wart* or polyp*)).ti,ab.    
5 "condyloma* acuminat*".ti,ab.    
6 "recurrent respiratory papilloma*".ti,ab.    
7 RRP.ti,ab.    
8 exp uterine cervix cancer/    
9 
(cervi* adj5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)).ti,ab. 
   
10 exp vulva cancer/    
11 
(vulva* adj5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)).ti,ab. 
   
12 exp vagina cancer/    
13 
(vagina* adj5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)).ti,ab. 
   
14 exp anus cancer/    
15 
((anal or anus) adj5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)).ti,ab. 
   
16 exp penis cancer/    
17 
((penile or penis) adj5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)).ti,ab. 
   
18 exp "head and neck cancer"/    
19 
((oral* or intra-oral* or intraoral* or "intra oral*" or gingiva* or orophary* or mouth* or tongue* or tonsil* or 
cheek* or gum* or palatal* or palate* or "head and neck") adj5 (cancer* or neoplasm* or malignan* or 
tumor* or tumour* or carcinom* or adenocarcinom*)).ti,ab. 
   
Page 39 of 90
https://mc.manuscriptcentral.com/sti
Sexually Transmitted Infections
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
20 exp larynx cancer/    
21 
((laryn* or pharyn* or vocal cord* or cordal or glott* or throat or voice box or subglott* or supraglott*) adj5 
(cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or adenocarcinom*)).ti,ab. 
   
22 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 
21 
   
23 Cost Utility Analysis/    
24 Quality Adjusted Life Year/    
25 "Quality of Life"/    
26 "quality of life".ti,kw.    
27 (health utilit* or utilit* measure* or utilit* instrument*).ti,ab.    
28 "Disutilit*".ti,ab.    
29 (QALY* or DALY*).ti,ab.    
30 (Quality adjusted life year* or Disability adjusted life year*).ti,ab.    
31 (EQ-5D or EQ5D or EQ-5D-3L or EQ-5D-5L).ti,ab.    
32 (SF-12 or SF12).ti,ab.    
33 (SF-6D or SF6D).ti,ab.    
34 (HUI or "H.U.I").ti,ab.    
35 (SF-36 or SF36).ti,ab.    
36 time trade off.ti,ab.    
37 standard gamble.ti,ab.    
38 cost*.ti,ab,kw.    
39 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38    
40 
(America* or Australia* or Austria* or Belgium or Belgian or Britain or British or Canad* or Chile or Chilean 
or Czech or Denmark or Danish or Estonia* or Finland or Finnish or France or French or German* or 
Hungary or Hungarian or Iceland* or Ireland or Irish or Italy or Italian or Japan* or Korea* or Luxembourg 
or Mexico or Mexican or Netherlands or Dutch or New Zealand* or Norway or Norwegian or Poland or 
Polish or Portug* or Slovak* or Slovenia* or Spain or Spanish or Sweden or Swedish or Switzerland or 
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Swiss or Turkey or Turkish or United Kingdom or United States).in,ti,hw,ab,ad,kw. 
41 United Kingdom/ or europe/ or exp western europe/    
42 (national health service* or nhs*).in,ti,hw,ab,ad,kw.    
43 
(english not ((published or publication* or translat* or written or language* or speak* or literature or 
citation*) adj5 english)).ti,ab. 
   
44 
(gb or "g.b." or britain* or british or uk or "u.k." or united kingdom* or england* or ireland* or irish* or 
scotland* or scottish* or wales or welsh).in,ti,hw,ab,ad,kw. 
   
45 
(bath or "bath's" or birmingham or "birmingham's" or bradford or "bradford's" or brighton or "brighton's" or 
bristol or "bristol's" or carlisle* or "carlisle's" or cambridge or "cambridge's" or canterbury or "canterbury's" 
or chelmsford or "chelmsford's" or chester or "chester's" or chichester or "chichester's" or coventry or 
"coventry's" or derby or "derby's" or durham or "durham's" or ely or "ely's" or exeter or "exeter's" or 
gloucester or "gloucester's" or hereford or "hereford's" or hull or "hull's" or lancaster or "lancaster's" or 
leeds* or leicester or "leicester's" or lincoln or "lincoln's" or liverpool or "liverpool's" or london or "london's" 
or manchester or "manchester's" or newcastle or "newcastle's" or norwich or "norwich's" or nottingham or 
"nottingham's" or oxford or "oxford's" or peterborough or "peterborough's" or plymouth or "plymouth's" or 
portsmouth or "portsmouth's" or preston or "preston's" or ripon or "ripon's" or salford or "salford's" or 
salisbury or "salisbury's" or sheffield or "sheffield's" or southampton or "southampton's" or st albans or 
stoke or "stoke's" or sunderland or "sunderland's" or truro or "truro's" or wakefield or "wakefield's" or wells 
or westminster or "westminster's" or winchester or "winchester's" or wolverhampton or "wolverhampton's" 
or worcester or "worcester's" or york or "york's").in,ti,hw,ab,ad,kw. 
   
46 
(bangor or "bangor's" or cardiff or "cardiff's" or newport or "newport's" or st asaph or "st asaph's" or st 
davids or swansea or "swansea's").in,ti,hw,ab,ad,kw. 
   
47 
(aberdeen or "aberdeen's" or dundee or "dundee's" or edinburgh or "edinburgh's" or glasgow or 
"glasgow's" or inverness or perth or stirling or "stirling's").in,ti,hw,ab,ad,kw. 
   
48 
(armagh or "armagh's" or belfast or "belfast's" or lisburn or "lisburn's" or londonderry or "londonderry's" or 
derry or "derry's" or newry or "newry's").in,ti,hw,ab,ad,kw. 
   
49 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48    
50 22 and 39 and 49    
51 limit 50 to english language    
52 ("Conference Abstract" or "conference paper" or "Conference review" or letter or note).pt.    
53 51 not 52    
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Ebsco Cinahl 
S1 ( anogenital N3 (wart* or polyp*) ) OR ( genital N3 (wart* or polyp*) ) OR ( (anal or anus) N3 (wart* or 
polyp*) )  
S2 recurrent respiratory papilloma*  
S3 RRP  
S4 MH "Cervix Neoplasms+"  
S5 cervi* N5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or adenocarcinom*)
  
S6 vulva* N5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or adenocarcinom*)
  
S7 (MH "Vulvar Neoplasms")  
S8 (MH "Vaginal Neoplasms")  
S9 vagina* N5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or adenocarcinom*)
  
S10 (MH "Anus Neoplasms+")  
S11 (anal OR anus) N5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)  
S12 (MH "Penile Neoplasms")  
S13 (penile OR penis) N5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or 
adenocarcinom*)  
S14 (MH "Head and Neck Neoplasms+") 
S15 (oral* or intra-oral* or intraoral* or "intra oral*" or gingiva* or orophary* or mouth* or tongue* or tonsil* or 
cheek* or gum* or palatal* or palate* or "head and neck") N5 (cancer* or neoplasm* or malignan* or tumor* or 
tumour* or carcinom* or adenocarcinom*)  
S16 (laryn* OR pharyn* OR vocal cord* OR cordal OR glott* OR throat OR voice box OR subglott* OR 
supraglott*) N5 (cancer* or neoplasm* or malignan* or tumor* or tumour* or carcinom* or adenocarcinom*)  
S17 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR 
S14 OR S15 OR S16  
S18 (MH "Costs and Cost Analysis")  
S19 (MH "Quality of Life")  
S20 (MH "Quality-Adjusted Life Years")  
S21 TI "quality of life" OR SU "quality of life"  
S22 health utilit* OR utilit* measure* OR utilit* instrument*  
S23 disutilit*  
S24 QALY* OR DALY*  
S25 Quality adjusted life year* OR Disability adjusted life year*  
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S26 EQ-5D OR EQ5D OR EQ-5D-3L OR EQ-5D-5L  
S27 SF-12 OR SF12  
S28 SF-6D OR SF6D  
S29 HUI or "H.U.I"  
S30 SF-36 OR SF36  
S31 time trade off  
S32 standard gamble  
S33 cost*  
S34 S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR 
S30 OR S31 OR S32 OR S33  
S35 America* or Australia* or Austria* or Belgium or Belgian or Britain or British or Canad* or Chile or 
Chilean or Czech or Denmark or Danish or Estonia* or Finland or Finnish or France or French or German* or 
Hungary or Hungarian or Iceland* or Ireland or Irish or Italy or Italian or Japan* or Korea* or Luxembourg or 
Mexico or Mexican or Netherlands or Dutch or New Zealand* or Norway or Norwegian or Poland or Polish or 
Portug* or Slovak* or Slovenia* or Spain or Spanish or Sweden or Swedish or Switzerland or Swiss or Turkey or 
Turkish or United Kingdom or United States  
S36 (MH "United Kingdom+")  
S37 national health service* or nhs*  
S38 gb or "g.b." or britain* or british or uk or "u.k." or united kingdom* or england* or ireland* or irish* or 
scotland* or scottish* or wales or welsh  
S39 bath or "bath's" or birmingham or "birmingham's" or bradford or "bradford's" or brighton or "brighton's" or 
bristol or "bristol's" or carlisle* or "carlisle's" or cambridge or "cambridge's" or canterbury or "canterbury's" or 
chelmsford or "chelmsford's" or chester or "chester's" or chichester or "chichester's" or coventry or "coventry's" or 
derby or "derby's" or durham or "durham's" or ely or "ely's" or exeter or "exeter's" or gloucester or "gloucester's" 
or hereford or "hereford's" or hull or "hull's" or lancaster or "lancaster's" or leeds* or leicester or "leicester's" or 
lincoln or "lincoln's" or liverpool or "liverpool's" or london or "london's" or manchester or "manchester's" or 
newcastle or "newcastle's" or norwich or "norwich's" or nottingham or "nottingham's" or oxford or "oxford's" or 
peterborough or "peterborough's" or plymouth or "plymouth's" or portsmouth or "portsmouth's" or preston or 
"preston's" or ripon or "ripon's" or salford or "salford's" or salisbury or "salisbury's" or sheffield or "sheffield's" or 
southampton or "southampton's" or st albans or stoke or "stoke's" or sunderland or "sunderland's" or truro or 
"truro's" or wakefield or "wakefield's" or wells or westminster or "westminster's" or winchester or "winchester's" or 
wolverhampton or "wolverhampton's" or worcester or "worcester's" or york or "york's"  
S40 bangor or "bangor's" or cardiff or "cardiff's" or newport or "newport's" or st asaph or "st asaph's" or st 
davids or swansea or "swansea's"  
S41 aberdeen or "aberdeen's" or dundee or "dundee's" or edinburgh or "edinburgh's" or glasgow or 
"glasgow's" or inverness or perth or stirling or "stirling's"  
S42 armagh or "armagh's" or belfast or "belfast's" or lisburn or "lisburn's" or londonderry or "londonderry's" or 
derry or "derry's" or newry or "newry's"  
S43 (MH "Europe")  
S44 S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43  
S45 S17 AND S34 AND S44  
Page 43 of 90
https://mc.manuscriptcentral.com/sti
Sexually Transmitted Infections
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Scopus 
( TITLE-ABS-KEY ( ( anogenital  OR  genital  OR  anal  OR  anus )  W/3  ( wart*  OR  polyp* ) )  OR  TITLE-ABS-
KEY ( "condyloma* acuminat*" )  OR  TITLE-ABS-KEY ( "recurrent respiratory papilloma*" ) )  OR  ( TITLE-ABS-
KEY ( ( cervi*  OR  vulva*  OR  vagina*  OR  anal  OR  anus  OR  penile  OR  penis  OR  oral*  OR  intra-oral*  
OR  intraoral*  OR  "intra oral*"  OR  gingiva*  OR  orophary*  OR phary* OR  mouth*  OR  tongue*  OR  tonsil*  
OR  cheek*  OR  gum*  OR  palatal*  OR  palate*  OR  "head and neck"  OR  laryn*  OR pharyn* OR  "vocal 
cord*"  OR  cordal  OR  glott*  OR  throat  OR  "voice box"  OR  subglott*  OR  supraglott* )  W/5  ( cancer*  OR  
neoplasm*  OR  malignan*  OR  tumor*  OR  tumour*  OR  carcinom*  OR  adenocarcinom* ) ) )   
AND   
( TITLE-ABS-KEY ( cost* )  OR  TITLE-ABS-KEY ( "health utilit*"  OR  "utilit* measure*"  OR  "utilit* instrument*" )  
OR  TITLE-ABS-KEY ( disutilit*  OR  qaly*  OR  qaly*  OR  "Quality adjusted life year*"  OR  "Disability adjusted 
life year*" )  OR  TITLE-ABS-KEY ( eq-5d  OR  eq5d  OR  eq-5d-3l  OR  eq-5d-5l  OR  sf-12  OR  sf12  OR  sf-6d  
OR  sf6d  OR  sf-36  OR  sf36  OR  hui  OR  "H.U.I" )  OR  TITLE-ABS-KEY ( "time trade off"  OR  "standard 
gamble" )  OR  TITLE ( "quality or life" )  OR  KEY ( "quality of life" ) )   
AND   
( TITLE-ABS-KEY ( america*  OR  australia*  OR  austria*  OR  belgium  OR  belgian  OR  britain  OR  british  
OR  canad*  OR  chile  OR  chilean  OR  czech  OR  denmark  OR  danish  OR  estonia*  OR  finland  OR  
finnish  OR  france  OR  french  OR  german*  OR  hungary  OR  hungarian  OR  iceland*  OR  ireland  OR  irish  
OR  italy  OR  italian  OR  japan*  OR  korea*  OR  luxembourg  OR  mexico  OR  mexican  OR  netherlands  OR  
dutch  OR  "New Zealand*"  OR  norway  OR  norwegian  OR  poland  OR  polish  OR  portug*  OR  slovak*  OR  
slovenia*  OR  spain  OR  spanish  OR  sweden  OR  swedish  OR  switzerland  OR  swiss  OR  turkey  OR  
turkish  OR  "United Kingdom"  OR  "United States"  OR  europe )  OR  AFFIL ( america*  OR  australia*  OR  
austria*  OR  belgium  OR  belgian  OR  britain  OR  british  OR  canad*  OR  chile  OR  chilean  OR  czech  OR  
denmark  OR  danish  OR  estonia*  OR  finland  OR  finnish  OR  france  OR  french  OR  german*  OR  hungary  
OR  hungarian  OR  iceland*  OR  ireland  OR  irish  OR  italy  OR  italian  OR  japan*  OR  korea*  OR  
luxembourg  OR  mexico  OR  mexican  OR  netherlands  OR  dutch  OR  "New Zealand*"  OR  norway  OR  
norwegian  OR  poland  OR  polish  OR  portug*  OR  slovak*  OR  slovenia*  OR  spain  OR  spanish  OR  
sweden  OR  swedish  OR  switzerland  OR  swiss  OR  turkey  OR  turkish  OR  "United Kingdom"  OR  "United 
States"  OR  europe ) )  OR  ( TITLE-ABS-KEY ( gb  OR  "g.b."  OR  britain*  OR  british  OR  uk  OR  "u.k."  OR  
"united kingdom*"  OR  england*  OR  ireland*  OR  irish*  OR  scotland*  OR  scottish*  OR  wales  OR  welsh  
OR  "national health service*"  OR  nhs* )  OR  AFFIL ( gb  OR  "g.b."  OR  britain*  OR  british  OR  uk  OR  
"u.k."  OR  "united kingdom*"  OR  england*  OR  ireland*  OR  irish*  OR  scotland*  OR  scottish*  OR  wales  
OR  welsh  OR  "national health service*"  OR  nhs* ) )  OR  ( TITLE-ABS-KEY ( bath*  OR  birmingham*  OR  
bradford*  OR  brighton*  OR  bristol*  OR  carlisle*  OR  cambridge*  OR  canterbury*  OR  chelmsford*  OR  
chester*  OR  chichester*  OR  coventry*  OR  derby*  OR  durham*  OR  ely*  OR  exeter*  OR  gloucester*  OR  
hereford*  OR  hull*  OR  lancaster*  OR  leeds  OR  leicester*  OR  lincoln*  OR  liverpool*  OR  london*  OR  
manchester*  OR  newcastle*  OR  norwich*  OR  nottingham*  OR  oxford*  OR  peterborough*  OR  plymouth*  
OR  portsmouth*  OR  preston*  OR  ripon*  OR  salford*  OR  salisbury*  OR  sheffield*  OR  southampton*  OR  
albans*  OR  stoke*  OR  sunderland*  OR  truro*  OR  wakefield*  OR  wells  OR  westminster*  OR  winchester*  
OR  wolverhampton*  OR  worcester*  OR  york* )  OR  AFFIL ( bath*  OR  birmingham*  OR  bradford*  OR  
brighton*  OR  bristol*  OR  carlisle*  OR  cambridge*  OR  canterbury*  OR  chelmsford*  OR  chester*  OR  
chichester*  OR  coventry*  OR  derby*  OR  durham*  OR  ely*  OR  exeter*  OR  gloucester*  OR  hereford*  OR  
hull*  OR  lancaster*  OR  leeds  OR  leicester*  OR  lincoln*  OR  liverpool*  OR  london*  OR  manchester*  OR  
newcastle*  OR  norwich*  OR  nottingham*  OR  oxford*  OR  peterborough*  OR  plymouth*  OR  portsmouth*  
OR  preston*  OR  ripon*  OR  salford*  OR  salisbury*  OR  sheffield*  OR  southampton*  OR  albans*  OR  
stoke*  OR  sunderland*  OR  truro*  OR  wakefield*  OR  wells  OR  westminster*  OR  winchester*  OR  
wolverhampton*  OR  worcester*  OR  york* ) )  OR  ( TITLE-ABS-KEY ( bangor*  OR  cardiff*  OR  newport*  OR  
st  "st asaph*"  OR  "st davids"  OR  swansea*  OR  aberdeen*or  dundee*  OR  edinburgh*  OR  glasgow*  OR  
inverness  OR  perth*  OR  stirling*  OR  armagh*  OR  belfast*  OR  lisburn*  OR  londonderry*  OR  derry*  OR  
newry* )  OR  AFFIL ( bangor*  OR  cardiff*  OR  newport*  OR  st  "st asaph*"  OR  "st davids"  OR  swansea*  
OR  aberdeen*or  dundee*  OR  edinburgh*  OR  glasgow*  OR  inverness  OR  perth*  OR  stirling*  OR  
armagh*  OR  belfast*  OR  lisburn*  OR  londonderry*  OR  derry*  OR  newry* ) )   
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AND NOT  INDEX ( Medline  OR  embase )  AND  ( LIMIT-TO ( LANGUAGE ,  "English" ) )  AND  ( EXCLUDE ( 
DOCTYPE ,  "cp" ) ) 
 
NHS EED via Cochrane Library 
#1 MeSH descriptor: [Condylomata Acuminata] explode all trees 
#2 "recurrent respiratory papilloma*"  
#3 MeSH descriptor: [Uterine Cervical Neoplasms] explode all trees 
#4 MeSH descriptor: [Vulvar Neoplasms] explode all trees 
#5 MeSH descriptor: [Vaginal Neoplasms] explode all trees 
#6 MeSH descriptor: [Anus Neoplasms] explode all trees 
#7 MeSH descriptor: [Penile Neoplasms] explode all trees 
#8 MeSH descriptor: [Head and Neck Neoplasms] explode all trees 
#9 {or #1-#8} 
 
 
 
 
 
 
 
 
 
 
Page 45 of 90
https://mc.manuscriptcentral.com/sti
Sexually Transmitted Infections
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Appendix 2 
Article title. 
Systematic review (with meta-analysis) of non-cervical HPV-related disease management costs and quality of life estimates applicable to the English setting. 
Author information:  
Koh Jun Ong, Marta Checchi, Lorna Burns, Charlotte Pavitt, Maarten Postma, Mark Jit 
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Relevant data extracted from the papers 
 
1. Population, HPV-related disease studied, disease stage, country, setting (e.g. hospital, general practices, sexual health clinics), study perspective 
(e.g. health care payer, patient); 
2. For costs, methods for cost measurement (e.g. micro-costing, tariff-based costing), currency and value year, types of costs included and perspective 
where reported, any discounting applied and discount rates; 
3. For utility, instruments used for value elicitation (e.g. EQ-5D scored using country-specific population norms), any information about duration of 
disutility, including survival/mortality for the HPV-related disease, if reported, perspective (patient or carers) and discounting and discount rates 
used. Disease-specific quality of life assessment tools used alongside direct/indirect utility elicitation methods were noted but their results were not 
recorded. 
Page 47 of 90
https://mc.manuscriptcentral.com/sti
Sexually Transmitted Infections
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Table 1 Extracts of AGW management costs reported in selected papers, some cost values had been adjusted to 2016/17 US 
Dollars (US$) for ease of comparison between studies 
No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
1 Coles, 2016 [1]; United 
Kingdom; Number of visits 
and treatment required 
estimated by GUM clinic 
experts; resource needs 
then combined with 
relevant national tariffs; 
GBP; 2012; Sanofi Pasteur 
MSD 
Average cost per 
patient in: 
              
England £265       $343     
Scotland £254             
Wales £264             
Northern Ireland £262             
                    
2 Lanitis, 2012 [2]; United 
Kingdom; Secondary GUM 
clinic data from HPA and 
primary care data from 
Health Improvement 
Network; Costs - National 
Health Service Payment by 
Results tariff; GBP; 2010; 
Sanofi Pasteur MSD 
Cost per GUM episode £288             
cost per treated Genital 
Wart Episode 
£276       $371 $367 $374 
                
   Per episode 
(£) 
Per female 
episode (£) 
Per male 
episode (£) 
        
First attack 291 291 291         
Recurrent 290 290 290         
Persistent 271 271 271         
Primary care 50 53 48         
Total GW patients 276 273 278         
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No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
3 Desai, 2011 [3]; England; 
Cost of care in both GP 
and GUM clinics 
considered; unit cost 
obtained from national 
tariffs; GBP; 2008; 
Department of Health 
  Estimated cost 
per episode of 
care for all 
settings 
95% CI 
(min.) 
95% CI 
(max.) 
        
Overall £113 £104 £121   $157 $145 $169 
Male £97 £87 £107   $135 $121 $149 
Female £129 £117 £140   $180 $163 $195 
                    
4 Woodhall, 2011 [4]; 
England and Northern 
Ireland; Case note review 
used to identify cost of an 
episode of care; GBP; 
2010; Department of 
Health 
Mean cost per episode 
of care (£), excluding 
STI screen 
  95% CI 
(min.) 
95% CI 
(max.) 
        
All (n = 895) £94 £84 £104   $126 $113 $140 
Male (n = 494) £80 £67 £92   $108 $90 $124 
Female (n = 400) £109 £94 £124   $147 $126 $167 
                    
5 Woodhall, 2009 [5]; 
England; Retrospective 
case note review of 
patients diagnosed with 
AGW attending a York 
GUM clinic informed 
treatment cost and 
duration of an episode of 
care; US dollars (GBP); 
2007; Department of 
Health 
Mean cost of an 
episode of care 
  95% CI 
(min.) 
95% CI 
(max.) 
        
Overall (n = 189) $286 (£139) $246 $327   $207 $178 $236 
Male (n = 93) $280 $237 $324   $202 $171 $234 
Female (n = 96) $292 $254 $331   $211 $184 $239 
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No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
                    
6 Brown, 2006 [6]; United 
Kingdom; AGW treatment 
patterns including drugs 
used, procedures and 
number of visits were 
recorded using a 
standardised 
questionnaire and 
completed by six GUM 
clinic clinicians; Treatment 
patterns obtained from 
incidence AGW cases and 
second and third line 
treatments for 
recurrent/persistent 
cases; Mean event rates 
used to construct 
treatment patterns; GUM 
clinic visit costs estimated 
based on retrospective 
chart review of time spent 
per visit (initial and follow-
up); Units of each 
resource required then 
combined with literature 
and UK standard 
reference price e.g. PSSRU 
and BNF; GBP; 2003; 
Sanofi Pasteur MSD 
From Table 4               
incident AGW cost £10,125,343             
recurrent AGW cost £8,282,244             
persistent AGW cost £3,994,744             
incident AGW cases £76,457             
recurrent AGW cases £38,902             
persistent AGW cases £16,755             
incident AGW cost per 
case 
£132             
recurrent AGW cost per 
case 
£213             
persistent AGW cost 
per case 
£238             
average cost per case £170 Note: Direct 
sum total 
spend 
divided by 
total cases 
    $281     
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No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
7 Langley, 2004 [7]; England 
and Wales; Case notes 
review of 100 males and 
100 females seen in each 
six GUM clinics; four 
components that make up 
treatment costs include 
labour costs, meterial 
costs, extra costs and 
indirect costs; Labour 
costs calculated based on 
direct observation and 
discussions with study 
sites; Material costs 
included total expenses 
for materials used to 
administer treatment; 
Extra costs included 
specific tests performed 
during visits that are on 
top of specific AGW 
treatment and included 
sexual health screens; 
Indirect costs included 
remaining departmental 
expenses; GBP; 2004; 
Funding source not 
specified, first author was 
affiliated with 3M 
Pharmaceuticals, USA 
Aggregate estimate of 
labour costs, material 
costs, extra costs, 
indirect costs - study 
site average 
              
Cost per successful 
outcome for external 
GW treatment 
              
Male £222       $355     
Female £211       $338     
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No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
8 Pirotta, 2009 [8]; 
Australia; Retrospective 
analysis of national cross-
sectional database and 
standard GP tariff used to 
estimate cost per GP visit, 
pathology costs not 
considered as data not 
available, hospitalisation 
costs based on hospital 
tariff; Database extraction 
covers period 2000-2007; 
Australian dollars; 2008-
09; Study used data from 
the BEACH programme 
funded by the National 
Prescribing Service Ltd; 
the Australian 
government Department 
of Health and Ageing; 
AstraZeneca Pty Ltd 
(Australia); Janssen-Cilag 
Pty Ltd; Merck, Sharp and 
Dohme (Australia) Pty Ltd; 
Roche Products Pty Ltd; 
Sanofi-Aventis Australia 
Pty Ltd; the Australian 
government Department 
of Veterans’ Affairs; and 
the Department of 
Employment and 
Workplace Relations 
  Cost per case             
Male A$251       $170     
Female A$386       $261     
Page 52 of 90
https://mc.manuscriptcentral.com/sti
Sexually Transmitted Infections
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
          
9 Annemans, 2008 [9]; 
Belgium; Retrospective 
analysis of hospital 
database for year 2004 
combined with outpatient 
data collected using a 
panel of expert; Euros; 
2006; Sanofi Pasteur MSD 
  Mean total 
cost, 
healthcare 
payer 
perspective 
            
Male €314       $315     
Female €319       $320     
          
10 Marra, 2008 [10]; Canada; 
Retrospective data, 
including physician 
specialty, hospitalisation, 
and prescribing data, 
obtained from all AGWs 
seen in British Columbia in 
1998-2006; Canadian 
dollars; 2006; Funding 
source not specified, the 
authors acknowledged 
contributions by Dr Marc 
Brisson, who was 
employed by Merck Frosst 
Canada at the time of his 
contributions 
  Mean cost (SD) Median cost (IQR)       
Overall (n=43,586) 190.32 (1,004.21) 71.15 (117.50) $124 (657)   
Male 175.67 (1,136.25) 70.32 (104.14) $115 (743)   
Female 206.94 (828.90) 72.07 (144.33) $135 (542)   
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No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
11 Salo, 2013 [11]; Finland; 
National registry data 
provided diagnostic and 
treatment procedures, 
hospitalisation, outpatient 
visit and prescription data, 
which were combined 
with national unit costs. 
Index events were 
identified during 1999-
2008.; Euros; 2010; 
Funding source not 
specified, authors 
reported conflict of 
interest either through 
grants or employment 
from GlaxoSmithKline, 
Merck&Co. Inc, GSK 
Biologicals, and/or Sanofi 
Pasteur MSD 
  Average 
undiscounted 
cost per HPV 
related AGW 
SD Not clear 
what overall 
average cost 
per case 
would be 
        
Primary health care €165 75     $190                                     
86  
Secondary health care €386 508     $445                                   
585  
n 4000 women, 70% 
treated in 
primary 
health care 
          
          
12 Herse, 2011 [12]; Finland; 
Registry data over years 
2001-2005 was used to 
estimate average annual 
AGW cases, their 
associated procedures and 
medications. Costs were 
informed by published 
costs (Hujanen et al., 
2008); 2 cost scenarios 
presented, min. (where 
  Total health 
care cost 
Calculated 
mean cost 
          
min. scenario €2,072,994 €669     $2,079,657 $671   
max. scenario €5,602,074 €1,808     $5,620,079 $1,814   
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No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
outpatient visit costs were 
estimated from number of 
visits recorded and 
average visit cost) and 
max. (where all costs in 
min. scenario included 
and outpatient 
procedures done by 
specialists and primary 
care costs); estimated 
3098 patients in year 
2005; Euros; 2006; Sanofi 
Pasteur MSD 
          
13 Hillemanns, 2008 [13]; 
Germany; Specialist 
physicians retrospectively 
extracted resource use 
data over preceding 12 
months for AGW patients 
seen for care between 9 
February and 6 April 2005; 
Resource use data was 
available for 617 patients 
(233 males, 384 females), 
mean age 32.0±10.0 
years; Euros; 2004; Sanofi 
Pasteur MSD 
  Mean annual 
direct cost per 
patient 
Range (min.) Range 
(max.) 
        
New cases               
Male (n=160) €315 €235 €407   $358 $267 $461 
Female (n=268) €414 €322 €506   $469 $365 $574 
Recurrent cases               
Male (n=37) €434 €230 €695   $492 $261 $788 
Female (n=55) €732 €476 €1,047   $829 $539 $1,186 
Resistant cases               
Male (n=17) €700 €228 €1,431   $793 $259 $1,622 
Female (n=19) €1,563 €842 €2,428   $1,771 $954 $2,752 
          
14 Gianino, 2013 [14]; Italy;   Mean cost ±           
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No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
Retrospective 
observational study using 
outpatient medical 
records to identify 
patients who visited 1 STI 
clinic in Italy; Selected 
AGW episodes that 
cleared in 18 months from 
initial visit; Analyses 
included 450 episodes 
(297 males, 153 females); 
Euros; 2011; Sanofi 
Pasteur MSD SpA 
(diagnosis and 
treatment) 
Overall (n=450) €158 257.77     $175                                   
284  
Male (n=297) €157 253.17           
Female (n=153) €161 267.3           
15 Baio, 2012 [15]; Italy; 
Used available secondary 
data in Italy, identified via 
literature review, to 
estimate lifetime cost per 
case of disease and 
merged with relative HPV 
6, 11, 16, and 18 
prevalence data to 
estimate total HPV-
attributable burden; 
secondary data source for 
AGW based on Merito et 
al. (2008); Euros; 2011; No 
funding to report 
Lifetime cost per case               
Male €470       $518     
Female €663       $730     
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No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
16 Merito, 2008 [16]; Italy; 
Retrospective 
observational study 
conducted among STI 
clinic clinicians, resource 
use data collected via 
medical chart review, 
included patients aged 14-
64 years with 
new/recurrent/resistant 
AGWs in year 2005; Euros; 
2005; Sanofi Pasteur MSD 
SNC (Lyon, France) 
  Mean annual 
direct cost per 
patient 
Range (min.) Range 
(max.) 
        
Male (n=189) €242 €176 €326   $257 $187 $346 
Female (n=152) €332 €254 €425   $352 $269 $451 
          
17 Dee, 2009 [17]; Ireland; 
Prospective resource use 
data collection over a 3-
week period (September 
to November 2007) in five 
GUM clinics representing 
defined urban/rural area 
mix; total 217 patients 
had AGWs; Euros; Not 
reported, assume 2007; 
Funding source not 
specified 
  Average 
annual cost 
per AGW 
patient 
Range (min.) Range 
(max.) 
        
Overall €335 €326 €344   $356 $346 $366 
Male €300             
Female €366             
          
18 Van Der Meijden, 2002 
[18]; Netherlands; 
  Average total 
cost 
Range (min.) Range 
(max.) 
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No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
Retrospective analysis of 
patient records identified 
over period 1 January 
1998 to 31 December 
1999, across largest health 
care providers in 3 largest 
cities in the Netherlands 
(total 3 dermatology 
clinics); Euros; Unknown, 
assume 2000; Funding 
source not specified, last 
author was affiliated with 
3M Pharmaceuticals, USA 
Overall (both 
completed and 
incomplete episode of 
care) 
              
Male €190 €155 €228         
Female €222 €165 €288         
Completed episode of 
care 
              
Male €221 €196 €270         
Female €292 €187 €378         
Incomplete episode of 
care 
              
Male €147 €64 €199         
Female €157 €98 €212         
Cost per successful 
outcome 
              
Male €485 €219 €624   $576 $261 $742 
Female €396 €225 €566   $470 $267 $673 
                    
19 Castellsague, 2009 [19]; 
Spain; Multicentre 
retrospective 
observational study 
covering public providers 
in six autonomous regions 
in Spain; Data on 
resources used to treat 
AGWs were 
  Adjusted 
mean cost per 
patient 
(95% CI 
lower) 
(95% CI 
upper) 
        
NHS perspective               
Overall €833       $883     
Male €673 €666 €682         
Female €1,040 €994 €1,073         
Societal perspective               
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No. Author, year; Country; 
Value elicitation method; 
Currency; Value year; 
Funding 
Reported value         US$ 
2016/17 
Range min. Range max. 
retrospectively collected 
from medical records over 
6 months (99 new cases) 
to 1 year (90 
recurrent/resistant 
AGWs); total 281 patients 
(128 males, 153 females); 
mean age 31+/-9 years; 
Euros; 2005; Sanofi 
Pasteur MSD 
Overall €1,056             
Male €927 €917 €941         
Female €1,223 €1,170 €1,265         
                    
20 Östensson-, 2015 [20]; 
Sweden; Annual AGW 
management and 
treatment costs estimated 
from a clinical expert 
panel, which estimated 
visits, procedures, and 
medications used; Euros; 
2009; Swedish Cancer 
Foundation, KI Cancer 
Strategic Grants, Swedish 
Research Council, and 
Stockholm County Council 
Total annual cost, 
Sweden 
€9,764,094             
Total number of AGW 
cases in 2009, Sweden 
28744             
Calculated average 
annual cost per AGW 
€340       $418     
 
Page 59 of 90
https://mc.manuscriptcentral.com/sti
Sexually Transmitted Infections
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Table 2 Extracts of non-cervical cancer management costs reported in selected papers, some cost values had been adjusted to 
2016/17 US Dollars (US$) for ease of comparison between studies 
No. Author, year, country; Disease; Country; 
Currency; Value year; Value elicitation method; 
Funding 
Reported value         USD 
2016/17 
Range 
min. 
Range 
max. 
1 Baio, 2012 [15]; Anal, head and neck, penile, 
vaginal, and vulvar cancer, and RRP; Italy; Euros; 
2011; Available Italian secondary data identified 
from literature review and used to estimat  
lifetime cost per case of HPV-related diseases; 
Sources for non-cervical cancer cost estimates 
derived mainly from Italian standard tariffs; No 
funding to report. 
Disease Lifetime 
direct costs 
per incident 
patient 
            
Anal cancer €11,742       $12,936     
Head and neck 
cancer 
€18,507       $20,389     
Vulvar cancer €13,330       $14,686     
Vaginal cancer €15,906       $17,524     
Penile cancer €10,048       $11,070     
RRP €187,428       $206,489     
                    
2 Olsen, 2012 [21]; Anal, penile, vaginal, and vulvar 
cancer; Denmark; Euros; 2008; Retrospective 
data extraction using the Danish national 
registers to identify anal cancer patients 
diagnosed in 2004-2007. The authors identified 
health care resources use for the year prior to 
diagnosis and for the first, second, and third year 
after diagnosis. Discounting at 3% per annum 
was applied to costs incurred in the second and 
third year after diagnosis. Standard hospital 
tariffs were used to estimate cost. Regression 
analysis was used to estimate hospital costs for 
anal (ICD-10 code C21), penile (C60), vaginal 
(C52), and vulvar cancers (C51). The paper took 
the perspective of hospital sector; Sanofi Pasteur 
MSD. 
  Total 
hospital cost 
per patient, 
including the 
year before 
diagnosis 
Total 
hospital cost 
per patient, 
excluding 
the year 
before 
diagnosis 
    Total 
hospital cost 
per patient, 
including the 
year before 
diagnosis 
    
Anal cancer               
Overall €38,289 €34,004     $51,571     
Male €41,347 €36,822     $55,690     
Female €36,734 €32,590     $49,477     
Penile cancer €20,513 €18,275     $27,629     
Vaginal cancer €25,435 €21,646     $34,258     
Vulvar cancer €21,161 €18,337     $28,502     
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No. Author, year, country; Disease; Country; 
Currency; Value year; Value elicitation method; 
Funding 
Reported value         USD 
2016/17 
Range 
min. 
Range 
max. 
                    
3 Borget, 2011 [22]; Anal, laryngeal, oral cavity, 
oropharyngeal, penile, pharyngeal, vaginal, and 
vulvar cancer; France; Euros; 2007; Resource use 
data extracted from the French national hospital 
database, outpatient and daily allowance costs 
were derived from the French National Institute 
of Cancer report, 2007; Sanofi Pasteur MSD. 
Cancer type  Annual 
number of 
patients 
hospitalised  
 Mean 
annual 
hospital cost 
per patient  
(SD)         
Vulvar cancer                               
1,237  
€4,608 (4,183)   $4,896 (4,445)   
Vaginal cancer                                   
728  
€5,512 (4,574)   $5,857 (4,860)   
Anal cancer                               
3,711  
€5,478 (5,081)   $5,821 (5,399)   
Penile cancer                             
678  
€3,840 (3,160)   $4,080 (3,358)   
Oral cavity 
cancer 
                            
10,786  
€6,634 (6,530)   $7,049 (6,939)   
Oropharyngeal 
cancer 
                            
12,232  
€6,819 (6,726)   $7,246 (7,147)   
Pharyngeal 
cancer 
                              
9,718  
€6,838 (6,807)   $7,266 (7,233)   
Laryngeal 
cancer 
                              
9,516  
€5,599 (5,668)   $5,950 (6,023)   
                    
4 Keeping, 2014 [23]; Anal cancer; England; GBP; 
2010/11; Mathematical model used to illustrate 
treatment pathway and combined with national 
tariffs, used to calculate average treatment cost 
per patient; Hospital Episode Statistics (HES) data 
used to identify cases of squamous cell anal 
carcinoma seen for care over period 2006 to 
2011 (9 months data in 2010/11). Cost of care 
    range (min.) range 
(max.) 
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No. Author, year, country; Disease; Country; 
Currency; Value year; Value elicitation method; 
Funding 
Reported value         USD 
2016/17 
Range 
min. 
Range 
max. 
was obtained from national tariffs. A 
mathematical model, with a Markov model 
component to simulate disease progression and 
follow-up based on mode of primary treatment 
(chemo radiotherapy vs. radiotherapy), was used 
to calculate costs from diagnosis to follow-up, 
using data obtained from the Association of 
Coloproctology of Great Britain and Ireland's anal 
cancer position statement, supplemented as 
necessary by expert opinion; Sanofi Pasteur MSD. 
Average cost of 
treating a case 
of invasive anal 
cancer from 
referral through 
to either 
completion of 
follow-up or 
death (not 
taking into 
account of 
future inflation) 
£16,281 £14,143 £22,884   $21,884 $19,010 $30,759 
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2016/17 
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min. 
Range 
max. 
5 
 
Heitland, 2013 [24]; Anal cancer; Germany; 
Euros; 2008; Retrospective cross-sectional 
analysis of five German hospital databases for 
year 2008, covering hospitalisation, diagnosis-
related groups, major treatment category during 
hospital stay, inpatient rehabilitation and sick 
leave. The authors considered social insurance 
payers expenditure reflect direct hospital 
treatment and inpatient rehabilitation medical 
costs and did not consider outpatient 
management costs, patients' co-payments and 
out-of-pocket expenses. Main diagnosis code was 
anal cancer (ICD-10 code C21); Sanofi Pasteur 
MSD, Lyon, France. 
  No. of 
hospitalisati
on 
 Annual cost 
of anal 
cancer 
hospitalisati
on and 
inpatient 
rehabilitatio
n, excluding 
sick leaves  
          
Male                               
2,238  
€11,877,807     $15,998,145     
Female                               
3,536  
€18,947,967     $25,520,901     
Sum                               
5,774  
€30,825,774     $41,519,046     
                    
6 Abramowitz, 2010 [25]; Anal cancer; France; 
Euros; 2007; Retrospective analysis of French 
hospital database, including private hospital 
records, of anal cancers in 2006. These were 
combined with standard public and private 
hospital tariffs year 2007 and included indirect 
daily allowances costs paid for by the French 
social security system. The authors took the 
perspective of French healthcare-payer; Sanofi 
Pasteur MSD. 
Total number of 
anal cancer 
patients 
                              
3,711  
          
    Total annual 
cost (public and 
private hospital, 
outpatient, and 
daily allowances 
included) 
€38,249,981       $40,644,525     
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Reported value         USD 
2016/17 
Range 
min. 
Range 
max. 
                    
7 van der Linden, 2016 [26]; Head and neck cancer 
(recurrent and/or metastatic squamous cell 
carcinoma); Netherlands; Euros; 2013; 
Retrospective data collection covering years 
2006 to 2013 from six Dutch head and neck 
treatment centers of recurrent and/or metastatic 
head and neck squamous cell carcinomas. Data 
extracted included tumour characteristics, 
treatment patterns, disease progression, survival, 
adverse evetns, and resource use. Unit cost data 
from published literature was used; the 
Netherlands Organization for Health Research 
and Development (ZonMw) and Merck B.V.. 
  Mean total 
cost per 
patient 
 ±            
Overall €24,211 €22,432     $25,822     
                    
8 Klussmann, 2013 [27]; Head and neck cancer; 
Germany; Euros; 2008; Retrospective cross-
sectional analysis of five German hospital 
databases for year 2008, covering hospital 
treatment, inpatient rehabilitation and sick leave. 
The authors considered social insurance payers 
expenditure reflect direct hospital treatment and 
inpatient rehabilitation medical costs and did not 
consider outpatient management costs, patients' 
co-payments and out-of-pocket expenses. Main 
diagnosis codes for head and neck cancers 
included ICD-10 codes C01-C06, C09-C14 and 
C32; SPMSD. 
Cancer 
category, 
gender (ICD-10 
code) 
No. of 
hospitalisati
on 
 Annual cost 
of 
hospitalisati
on and 
inpatient 
rehabilitatio
n, excluding 
sick leaves  
          
Oral cavity, 
male (C02-C06) 
                            
11,929  
€79,091,226     $106,527,48
7 
    
Oral cavity, 
female (C02-
C06) 
                              
4,965  
€34,177,666     $46,033,689     
Oropharynx, 
male (C01, C09-
C10) 
                            
14,396  
€64,387,928     $86,723,706     
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Reported value         USD 
2016/17 
Range 
min. 
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Oropharynx, 
female (C01, 
C09-C10) 
                              
4,110  
€18,641,573     $25,108,220     
Pharynx other, 
male (C11-C13) 
                            
10,268  
€40,060,755     $53,957,585     
Pharynx other, 
female (C11-
C13) 
                              
1,908  
€7,155,015     $9,637,046     
Other/ill-
defined sites in 
the lip, oral 
cavity, and 
pharynx, male 
(C14) 
                                  
532  
€3,648,316     $4,913,894     
Other/ill-
defined sites in 
the lip, oral 
cavity, and 
pharynx, female 
(C14) 
                                  
129  
€872,291     $1,174,883     
Larynx, male 
(C32) 
                            
13,744  
€51,615,938     $69,521,190     
Larynx, female 
(C32) 
                              
1,876  
€7,116,289     $9,584,886     
Total, male                             
50,869  
€238,804,16
3 
    $321,643,86
3 
    
Total, female                             
12,988  
€67,962,834     $91,538,725     
Total, overall                             
63,857  
€306,766,99
7 
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9 Kim, 2011 [28]; head and neck cancer; UK; GBP; 
2008/09; Retrospective analysis using Hospital 
Episode Statistic (HES) data to estimate the post-
operative healthcare costs for an incidence 
cohort of squamous cell carcinoma of the head 
and neck patients (primary diagnosis in lip, 
tongue, oral cavity, pharynx or larynx, ICD-10: 
C00-6, C09-10, C12-4, C32) who underwent 
surgical resection between 1 July 2003 and 31 
March 2008 - mapped healthcare utilization to 
"national schedule of reference costs 2008-09 for 
NHS Trusts" and "Unit costs of health & social 
care 2009"; GlaxoSmithKline 
Mean cost of 
post-operative 
healthcare 
utilisation for 
resected 
patients w h&n 
cancer over 5 
years 
£23,212       $32,333     
Mean cost per 
year 1st year 
£19,778       $27,550     
Mean cost per 
year 2nd year 
£1,477       $2,057     
Mean cost per 
year 3rd year 
£847       $1,180     
Mean cost per 
year 4th year 
£653       $910     
Mean cost per 
year 5th year 
£455       $634     
Mean cost of 
post-operative 
healthcare 
utilisation for 
laryngeal 
cancer over 5 
years 
£28,981       $40,369     
Mean cost of 
post-operative 
healthcare 
utilisation for 
pharyngeal 
£25,827       $35,976     
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cancer over 5 
years 
Mean cost of 
post-operative 
healthcare 
utilisation for 
oral cavity 
cancer over 5 
years 
£25,311       $35,257     
Mean cost of 
post-operative 
healthcare 
utilisation for 
tongue cancer 
over 5 years 
£19,493       $27,153     
Mean cost of 
post-operative 
healthcare 
utilisation for 
lip cancer over 
5 years 
£5,790       $8,065     
Total cost of 
post-operative 
healthcare 
utilisation for 
cohort of 
resected h&n 
cancer (5 year 
f/u period) 
£255,500,00
0 
      $355,900,67
7 
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10 Lacau-, 2010 [29]; Head and neck cancer; France; 
Euros; Not explicitly stated, assume 2008; 
Retrospective analysis of the French national 
hospital database (PMSI) to extract year 2007 
number of head and neck cancer patients, 
recorded from both public and private hospitals. 
The authors took a healthcare payer persp ctive. 
Data extracted included hospital stays, 
chemotherapy and radiotherapy sessions. Costs 
were obtained from French official tariffs; Sanofi 
Pasteur MSD. 
Cancer type Annual 
number of 
patients 
 Total annual 
cost for all 
patients 
from payer 
perspective, 
including 
hospital 
costs, 
expensive 
drugs, 
indirect 
costs and 
outpatient 
costs and 
excluding 
rehabilitatio
n costs  
          
Oral cavity 
cancer 
                            
10,786  
€130,694,25
3 
    $176,031,28
8 
    
Salivary glands 
cancer 
                              
1,831  
€17,271,550     $23,262,945     
Oropharyngeal 
cancer 
                            
12,232  
€158,722,20
7 
    $213,781,96
8 
    
Pharyngeal 
cancer 
                              
9,718  
€125,582,77
1 
    $169,146,66
4 
    
Laryngeal 
cancer 
                              
9,516  
€98,251,871     $132,334,84
3 
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11 Van Agthoven, 2001 [30]; Head and neck cancer; 
Netherlands; Euros; 1996; Retrospective analysis 
of patients with confirmed cancer of the oral 
cavity, larynx or oropharynx diagnosis between 
1994 and 1996, accessing care in the University 
Hospital Rotterdam and the University Hospital 
Vrije Universiteit Amsterdam. The authors took 
an institutional perspective and only direct costs 
within healthcare, e.g. medical therapy costs. 
Total medical consumption of all patients were 
identified via micro-costing method based on a 
detailed inventory and measurement of 
resources consumed, combined with financial 
data, with future costs discounted at 4% per 
annum. A model was built that covers 10-year 
disease course, from diagnosis, treatment and 
follow-up of primary tumours in the first 2 years 
to treatment and follow-up of recurrences, and 
deaths, to up to 10 years. Modelled survival data 
was extracted from the Netherlands Cancer 
Registry; the Association 
of University Hospitals (VAZ). 
Head and neck 
cancer site 
 Average 
total 
discounted 
costs per 
new patient  
            
Oral cavity €35,541       $58,711     
Larynx €26,851       $44,356     
Oropharynx €35,642       $58,878     
Overall 
(weighted 
average of the 3 
cancer sties 
studied) 
€31,829       $52,579     
                    
12 Corbridge, 2000 [31]; Head and neck cancer; 
England; GBP; not stated, assume 2000 GBP; 
Prospective audit of inpatient care cost of 10 
patients referred to a head and neck clinic in 
Oxford. The personnel involved in patient care 
and materials used were documented. Only 
inpatient resource use documented, excluded 
any preoperative assessments as outpatients or 
day case admissions information not collected. 
Average min. 
total cost of 
treating a head 
and neck cancer 
in-patient 
£11,450       $21,683     
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No. Author, year, country; Disease; Country; 
Currency; Value year; Value elicitation method; 
Funding 
Reported value         USD 
2016/17 
Range 
min. 
Range 
max. 
Post-discharge care, readmissions or post-
treatment radiotherapy not accounted for. Audit 
also excluded patients receiving primary 
radiotherapy or palliative care; Funding source 
not specified. 
                    
13 Lowry, 1990 [32]; Head and neck cancer; UK; 
GBP; Not identified, assume 1990; Not specified; 
Funding source not specified 
Overall total 
cost for 
resection and 
reconstruction 
of head and 
neck 
malignancy 
including 
presurgical 
chemotherapy 
and 
postoperative 
radiotherapy 
£5,661       $16,784     
                    
14 van Agthoven, 2006 [33]; Laryngeal cancer; 
Netherlands; Euros; 2003; Retrospective 
observational study of laryngeal cancer patients 
in five Dutch university hospitals. Assessment 
was carried out to evaluate impact of new 
disease management guideline. Study period 
covered 1 January 1995 to 30 April 2001. Cost 
data was from hospital administrative 
departments and standard Dutch tariffs. The 
authors took a hospital perspective; Funding 
Type of 
laryngeal cancer 
n (post-
guideline 
implementat
ion) 
 Total 
treatment 
cost post-
guideline 
implementat
ion, mean  
          
Dysplasia                                     
16  
€3,005     $3,502     
Carcinoma in                                     €5,136     $5,985     
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No. Author, year, country; Disease; Country; 
Currency; Value year; Value elicitation method; 
Funding 
Reported value         USD 
2016/17 
Range 
min. 
Range 
max. 
source not specified. situ 23  
T1 carcinoma                                   
120  
€5,931     $6,912     
T2 carcinoma                                   
104  
€8,180     $9,533     
T3 carcinoma                                     
49  
€14,593     $17,006     
T4 carcinoma                                     
51  
€20,229     $23,574     
                    
15 Zavras, 2002 [34]; Oral cavity cancer; Greece; US 
dollars; 2001; Retrospective analysis of 95 
patients diagnosed with squamous cell 
carcinoma of the oral cavity (ICD-10 code C00.3-
C00.9, C01-C06) between 1 January 1993 and 31 
December 1999, extracted from medical records 
and clinic files of the Oral and Maxillofacial Clinic 
of the Athens General Hospital. Information 
extracted included length of hospitalisation, 
treatment, disease stage etc. Prices were 
obtained from official publications or 
professional association catalogues or average 
prices from 3 private hospitals when published 
sources were unavailable; National Institute of 
Dental Research funds (NIDCR/NIH, Bethesda, 
MD.). 
  Mean 
treatment 
cost per 
patient 
            
Overall $7,450       $9,372     
Stage I disease $3,662       $4,607     
Stage II disease $5,867       $7,381     
Stage III disease $10,316       $12,978     
Stage IV disease $11,467       $14,426     
                    
16 Preuss, 2007 [35]; Oropharyngeal carcinomas; 
Germany; Euros and US dollars; 2006; 
Retrospective analysis of 211 patients who 
presented to an otorhinolaryngology department 
  Euros  US dollars            
Surgery and €17,488 $22,097     $16,811     
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No. Author, year, country; Disease; Country; 
Currency; Value year; Value elicitation method; 
Funding 
Reported value         USD 
2016/17 
Range 
min. 
Range 
max. 
in Germany between 1992 and 2005. Patients 
were included if they have histologically 
confirmed squamous cell carcinoma diagnosis, 
suitable for curative surgical treatment. Study 
excluded patients with distant metastases. The 
authors analysed data on surgical complications, 
therapeutic morbidity, and treatment costs; 
Funding source not specified. 
postoperative 
radio(chemo)th
erapy, min. 
Surgery and 
postoperative 
radio(chemo)th
erapy, max. 
€24,631 $30,996     $23,582     
                    
17 Keeping, 2015 [36]; Penile cancer; England; GBP; 
2010/11; Hospital Episode Statistics (HES) data 
used to identify inpatient and outpatient activity 
associated with penile cancer, covering years 
2006/07 to 2010/11 (nine months provisional 
data for 2010/11). Resource needs combined 
with 2010/11 national tariffs. A mathematical 
model with a Markov model was used to 
estimate treatment cost per patient per case, 
informed by the European Association of 
Urologists Treatment Guidelines, modified; 
Sanofi Pasteur MSD. 
Table 3: Per 
patient 
treatment costs 
by scenario 
              
Scenario  Cost per 
Patient 
            
Base Case  Lower 
Bound  
Upper 
Bound 
        
No inflation, no 
MFF 
£7,421 £5,930 £10,104   $9,975 $7,971 $13,581 
Inflation, no 
MFF  
£7,465 £5,961 £10,156   $10,034 $8,012 $13,651 
No inflation, 
MFF  
                              
8,015  
£6,405 £10,913   $10,773 $8,609 $14,668 
Inflation, MFF                                
8,063  
£6,437 £10,968   $10,838 $8,652 $14,742 
(MFF, Market 
Force Factor) 
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No. Author, year, country; Disease; Country; 
Currency; Value year; Value elicitation method; 
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Reported value         USD 
2016/17 
Range 
min. 
Range 
max. 
18 Harrison, 2016 [37]; RRP; Scotland; GBP; 
2013/14; Questionnaire used to collect data 
during routine adult RRP follow-up in a single 
centre managing RRP in Glasgow, Scotland. Cost 
data sourced from Scottish Government's 
Information Services Division. Included 14 
patients (6 males and 8 females, mean age at 
diagnosis 36, range 12 to 66 years old) with 
active RRP between January 2013 and April 2014; 
Funding source not specified. 
Total treatment 
cost for 14 
patients from 
January 2013 to 
April 2014 
£107,478       $137,601     
                    
19 Salo, 2013 [11]; Vaginal and vulvar cancer; 
Finland; Euros; 2010; National registry data 
individually linked to health care registers 
provided diagnostic and treatment procedures, 
hospitalisations, outpatient visits and 
prescription data, as well as diagnostic and 
treatment procedures by private providers. 
These which were combined with national unit 
costs. Cancers recorded in the Cancer Registry in 
1990-2008 were includedIndex events were 
identified during 1999-2008 and cancers that 
were recorded in the Cancer Registry during 
1990-1998; Funding source not specified; some 
authors reported conflicts of interest either 
through grants or employment from 
GlaxoSmithKline, Merck&Co. Inc, GSK Biologicals, 
and/or Sanofi Pasteur MSD. 
   Average 
undiscounte
d cost per 
HPV related 
AGW  
 SD            
Vaginal cancer €24,424 26,760     $28,131     
Vulvar cancer €15,867 18,346     $18,275     
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Table 3 Details of studies reporting utility estimates for anogenital warts (AGWs) 
No. 
Author, year, c;Country; Utility elicitation method; 
Study details; Funding 
Results 
1 
Marcellusi, 2015;, Italy [38]; TTO and EQ-5D; 465 
patients with confirmed diagnosis of HPV-related 
disease e.g. anal cancer, head and neck cancer, or AGW, 
mean age 44.0 (SD 16.3) years and 135 controls, mean 
age 44.0 (SD 13.2) years enrolled over 31 October  2008 
to 31 July 2012. EQ-5D source, EuroQol, the 
Netherlands; Sanofi Pasteur MSD, Italy and partly 
funded by the Italian Ministry o fEducation, University 
and Scientific Research. 
 
n Mean age (SD) 
Mean (SD) EQ-5D utility for 
patients with AGW 
Mean (SD and 95% CI) TTO 
utility for patients with 
AGW 
AGW overall 132 33.1 (10.2) 0.9 (0.1) 
0.78 (SD 0.27; 95% CI 0.73-
0.82) 
Males 74 35.7 (10.2) 0.9 (0.1) 0.83 (95% CI: 0.77-0.88) 
Females 58 29.7 (9.3) 1 (0.1) 0.71 (95% CI: 0.64-0.79) 
 
2 
Vriend, 2014;, The Netherlands [39]; EQ-5D-3L, EQ-VAS, 
and genital wart-specific CECA-10 tool; Patients 
attending 9 STI clinics in the Netherlands for first or 
recurrent AGW episode between February and August 
2012 were eligible for recruitment. Single EQ-5D utility 
not reported, although figure with percentage of 
patients reporting some of severe problems with each 
of the five EQ-5D dimensions were presented, 
separately for women, men, and MSM. Actual 
proportions not stratified by some problems or severe 
problems not available, thefore not possible to calculate 
single utility score using population norms; No specific 
funding received. 
  EQ-VAS score from  
45 women 75.3% (95% CI: 70.3-80.2) 
34 heterosexual men 83.7% (95% CI: 79.3-88.2) 
14 MSM 82.1 (95% CI: 75.4-88.9) 
 
3 
Dominiak-Felden, 2013, ; UK [40]; EQ-5D; For AGW, 
participants were men and women clinic attendees who 
were either seen for first or recurrent AGW (n = 186) or 
had a history of AGW more than 6 months before (n = 
62) recruitment period between May 2008 and March 
2009; Sanofi Pasteur MSD. 
EQ-5D score adjusted by age and sex (SD) 0.9 (0.13) 
vs population norm 0.89, p = 
0.633 
VAS score adjusted by age and sex (SD) 78% (14.8%) vs UK general population 85% 
  EQ-5D score (crude) VAS score (crude) 
Men 0.89 (SD 0.17) 79 (SD: 15.5) 
Women 0.84 (SD 0.16) 75 (SD: 19.3) 
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No. 
Author, year, c;Country; Utility elicitation method; 
Study details; Funding 
Results 
4 
Shi-, 2012, ; China [41]; EQ-5D-3L, Chinese version, and 
EQ-VAS; EQ-5D index scores calculated using UK, US, 
and Japan population norms; 1,358 GW patients (612 
men, 746 women) enrolled between July 2007 to July 
2008 from 18 clinics across China were included in the 
analysis, with a mean age of 32.0 ± 10.6 years; MSD 
China. 
Overall VAS score 65.2 ± 22.0 
  Mean (SD) EQ-5D based on UK preference weight 
Overall 0.826 (0.201) 
Male 0.856 (0.185) 
Female 0.802 (0.210) 
 
5 
Drolet, 2011, ; Canada [42]; EQ-5D, VAS, SF-6D; 272 
patients with first or recurrent AGW between 
September 2006 and February 2008 recruited. EuroQol, 
SF-12, short Spielberg State-Trait Anxiety Inventory, and 
HPV impact profile measured at recruitment, and 2 and 
6 months later. British scoring system used to translate 
health states of study participants into EQ-5D utility 
scores; Merck Frosst Canada Ltd.. 
  EQ-5D total score VAS SF-6D 
Men    
Norm mean 89.1 82.3 NA 
All AGW cases at recruitment, n=127, mean 
(95% CI) 81.0 (77.4-84.5) 77.6 (74.9–80.2) 74.2 (72.0–76.5) 
AGW cleared at end of 6 months follow-up, 
n=47, mean (95% CI) 86.1 (79.8–92.3) 81.6 (76.8–86.5) 77.5 (73.2–81.8) 
AGW persisted at end of 6 months follow-up, 
n=80, mean (95% CI) 83.8 (78.5–89.1) 78.7 (75.8–81.6) 73.8 (70.3–77.4) 
Women    
Norm mean 88.6 83.2 NA 
All AGW cases at recruitment, n=145, mean 
(95% CI) 77.4 (74.0-80.8) 76.4 (73.9–78.9) 71.0 (69.0–73.0) 
AGW cleared at end of 6 months follow-up, 
n=87, mean (95% CI) 89.3 (84.6-94.0) 82.1 (78.6–85.7) 76.7 (73.8–79.4) 
AGW persisted at end of 6 months follow-up, 
n=58, mean (95% CI) 79.6 (73.4-84.7) 78.1 (73.5–82.8) 71.5 (67.8–75.2) 
Median duration of an AGW episode, n=51 incident cases: 125 days 
Average QALY loss per AGW case: 0.017 to 0.041 
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Author, year, c;Country; Utility elicitation method; 
Study details; Funding 
Results 
6 
Mennini, 2011, ; Italy [43]; TTO and EQ-5D (only at 
baseline); 36 patients with histologically confirmed 
CIN2-3 diagnosis eligible, identified between June 2007 
and October 2008. Patient given pathologic condition, 
which included AGWs, to elicit their TTO utility value. 
EQ-5D-3L used to assess patients' health status at 
baseline; Italian Ministry of Education, University and 
Scientific Research in Italy. 
Mean (SD) baseline EQ-5D utility in all 
women with HPV-related diseases 0.93 (0.10) 
  Mean (SD) TTO utility 
AGW 0.71 (0.35) 
 
7 
Senecal, 2011, ; Canada [44]; EQ-5D and EQ-VAS; 
Patients with first or recurrent AGW episode recruited 
between September 2006 and February 2008 across 
Canada. Data complete for 270 of 330 AGW patients 
recruited at diagnosis or follow-up for a first or 
recurrent episode. Questionnaire completed at 
recruitment, 2 and 6 months later. Mean age: 33.7 years 
(men); 29.5 years (women). EQ-5D values calculated 
based on Canadian population norms data, with 
additional analysis using US population norms.; Merck 
Frosst Canada Ltd. 
  Mean (95% CI) 
EQ-5D score (AGW patients) 0.789 (0.763-0.815) 
EQ-5D disutility vs Canadian norm 9.9 (7.3-12.5) 
EQ-5D disutility vs Canadian norm (males) 7.8 (4.1-11.5) 
EQ-5D disutility vs Canadian norm (females) 11.7 (8.3-15.2) 
EQ-VAS score (AGW patients) 0.769 (0.749-0.788) 
EQ-VAS disutility vs Canadian norm 6 (4.1-7.9) 
EQ-VAS disutility vs Canadian norm (males) 4.8 (2.0-7.5) 
EQ-VAS disutility vs Canadian norm (females) 7 (4.4-9.6) 
 
8 
Woodhall, 2011, ; England and Northern Ireland [4]; EQ-
5D-3L and EQ-VAS; 895 patients from a convenience 
sample of seven sexual health clinics in England and one 
in Northern Ireland. data collection took place between 
August 2009 and February 2010. Those who consented 
to follow-up were given another set of questionnaire 
two weeks after baseline visit. Utility values calculated 
based on UK population norms; Department of Health. 
  All (95% CI) Male (95% CI) Female (95% CI) 
EQ-5D index 0.87 (0.85-0.89) 0.88 (0.86-0.9) 0.87 (0.83-0.9) 
EQ-VAS 77 (76-79) 79 (77-80) 75 (71-78) 
EQ-5D disutility 0.056 (0.038-0.074) 0.043 (0.021-0.065) 0.063 (0.029-0.097) 
Duration episode of care (days) 36 (27-46) 35 (20-51) 37 (20-53) 
Prescription/recovery time (days) 36 (36-40) 39 (34-44) 37 (41-43) 
Time to attendance (days) at clinic 
after noticing GW 111 (88-135) 144 (112-174) 69 (48-90) 
Mean QALY loss (days) 6.6 (2.9-11.3) 6.6 (0.8-14.9) 6.5 (2.9-11.2) 
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Author, year, c;Country; Utility elicitation method; 
Study details; Funding 
Results 
9 
Marra, 2009, ; Canada [45]; EQ-5D and SF-6D; 75 
participants (52% female) with history of AGWs 
recruited using newspaper advertisements and 
completed QoL questionnaires considering health state 
when having AGWs. mean age 40 (SD 11.4) years. 
Scoring algorithm used UK-based York scoring system; 
Funding source not specified. 
Mean EQ-5D utility score 0.76 (SD: 0.19; 95% CI: 0.72-0.8) 
Mean EQ-5D VAS score 65.1 (SD: 21.2; 95% CI: 60-70) 
Mean SF-6D utility score 0.74 (SD: 0.13; 95% CI: 0.71-0.77) 
 
10 
Pirotta-, 2009, ; Australia [46]; EuroQoL VAS, HPV 
Impact Profile (HIP) and the Sheehan Disability Score 
(SDS); One group of study participants (n = 40) was 
women with AGW seen in a sexual health clinic in 
Melbourne in year 2006. Mean age (SD) for this group 
was 24 (5) years; CSL Limited. 
  Mean 
EuroQoL VAS, observed value 68.9 (SD: 21.4) 
Multivariate analysis (adjusted for age, ethnicity, and current partner) 71.4 (95% CI: 63.3-79.6) 
 
11 
Woodhall, 2009, ;  England [5]; EQ-5D (note: disutility 
value presented); 189 patients attending the York STD 
clinic in 2006/07; Department of Health 
EQ-5D disutility for 18-30 year olds 
Estimated loss of QALYs ranged from 0.0045 (95% CI: 0.0014–0.0078) to 0.023 (95% CI: 0.0072– 0.039). 
12 
Woodhall, 2008, ; England [47]; EQ-5D and EQ-VAS; 81 
York GUM attendees (43 men, 38 women, mean age 26 
years) recruited over 3-month period; Department of 
Health. 
  
Unadjusted mean EQ-5D index 
score 
Unadjusted mean EQ-VAS score 
Cases 0.9 72 
Controls 
(UK 
norms) 
0.91 86 
Note 
Age and sex adjusted mean EQ-
5D index score 0.039 points 
lower (95% CI 0.005-0.078; 
p=0.02) 
Age adjusted EQ-VAS, average difference lower by 13.9 (95% CI 
9.9-17.6; p<0.001), based on 70 cases; male cases lower by 10.9 
(95% CI 5.7-15.5; p<0.001); female cases lower by 19.9 (95% CI 
11.7-26.2; p<0.001) 
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Table 4 Summary details of papers reporting utility values for HPV-related cancers 
No. 
Author, year, c; Disease; Country; Utility elicitation method; 
Study details; Funding 
Results 
1 
Aro, 2016, ; Head and neck cancer, ; Finland [48]; 15D; 214 
patients treated for head and neck malignancy during years 
2007-2013 at their institution completed the 15D 
questionnaire; the Helsinki University Hospital Research Funds 
 
15D utility 
 
Population 0.911 
 
Patients 0.872 
 
Baseline 0.872 p-value vs baseline 
3 months 0.839 p < 0.001 
6 months 0.857 p = 0.001 
12 months 0.852 p = 0.003 
 
2 
Govers, 2016, ; Oral cancers, ; The Netherlands [49]; EQ-5D-3L, 
EQ-VAS, and shoulder disability questionnaire (SDQ); 174 
patients with early stage (T1-2) oral cavity squamous cell 
carcinoma between 2001 and 2013 completed EQ-5D-3L, EQ-
VAS, and SDQ. EQ-5D-3L converted to utility values using the 
Dutch tariff; None declared. 
Patient subgroup n 
Mean age (SD, 
range) 
Mean time 
after treatment 
in years (SD, 
range) 
Mean (SE) EQ-
5D-3L utility 
score, adjusted 
for age, gender, 
and time since 
treatment (p-
value 0.700) 
Mean (SE) EQ-
VAS score, 
adjusted for 
age, gender, 
and time since 
treatment (p-
value 0.234) 
watchful waiting (WW) 26 
71.4 (11.4, 54.8-
91.6) 
4.8 (1.8, 2.3-
9.2) 0.804 (0.04) 69.7 (3.7) 
sentinel lymph node 
biopsy (SLNB) 19 
63.6 (9.4, 44.9-
80.2) 
1.9 (1.4, 0.4-
4.1) 0.863 (0.05) 79.6 (4.8) 
supraomohyoid neck 
dissection (SOHND) 109 
62.7 (12.2, 29.5-
84.6) 
5.2 (2.6, 1.6-
12.2) 0.834 (0.02) 76.1 (1.8) 
modified radical neck 
dissection (MRND) 27 
64.8 (10.6, 40.5-
96.5) 
5.2 (3.2, 0.4-
11.0) 0.794 (0.04) 71.5 (3.3) 
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3 
Pickard, 2016, ; Head and neck cancer, ; US [50]; EQ-5D-3L 
(utility values calculated using US preference-based 
algorithm), EQ-VAS, and Functional Assessment of Cancer 
Therapy-General (FACT-G); Retrospective analysis on cross-
sectional clinical trial data that included cancer patients 
participating in a US-based multicentre study. 50 cancer 
patients were recruited for each tumour site studied, which 
included head/neck. All patients had received at least 2 cycles 
or at least 1 month of chemotherapy. Mean age 56.0 (SD: 9.2); 
Funding support for the original study was provided by 11 
pharmaceutical companies. 
  Mean (SD) 
Unadjusted EQ-5D 0.76 (0.15) 
EQ-5D index scores, adjusted for age and sex 0.828 
Unadjusted EQ-VAS 61.8 (21.7) 
EQ-VAS, adjusted for age and sex 60.8 
 
4 
Rettig, 2016, ; Head and neck cancer, sites include larynx, oral 
cavity, oropharynx, hypopharynx, nasopharynx, and nasal 
cavity/paranasal sinuses, US [51]; SF-36 to single score; 
Health-related quality of life (HRQOL) in individuals aged 65+ 
with head and neck squamous cell carcinoma who participated 
in the linked Surveillance, Epidemiology, and End Results-
Medicare Health Outcomes Survey (SEER-MHOS) database 
from 1998 to 2005 was extracted. Data included surveys 
assessing HRQOL from 5 years prediagnosis to 10 years 
postdiagnosis. HRQOL was measured using SF-36, with the 
physical component summary and the mental component 
summary scores combined to generate single HRQOL 
summary score; n = 1,653; National Institute of Dental and 
Craniofacial Research/National Institutes of Health Research 
Training in Otolaryngology grant, with statistical support 
provided in part by the Johns Hopkins Institute for Clinical and 
Translational Research 
Time 
HRQOL Score (95% 
CI) 
HRQOL Score (95% 
CI) 
HRQOL Score (95% 
CI) 
HRQOL Score (95% 
CI) 
  Overall, n = 1,653 
<2 Year Survivors, n = 
296 
2-5 Year Survivors, n 
= 209 
>5-Year Survivors, n = 
1,081 
Time interval 
prediagnosis 
        
5 y (Baseline) 92.3 (89.3, 95.2) 87.3 (92.7, 91.9) 92.8 (85.1, 100.5) 96.4 (91.8, 100.9) 
2 y 90.2 (88.4, 92.0) 86.3 (83.4, 89.2) 89.8 (85.3, 94.2) 94.5 (91.9, 97.1) 
Diagnosis: 0 y 85.0 (83.4, 86.6) 73.9 (70.3, 77.6) 82.9 (79.0, 86.9) 91.5 (89.4, 93.5) 
Time interval 
postdiagnosis 
        
13 mo 83.7 (82.0, 85.4) 69.7 (62.8, 76.7) 79.9 (76.1, 83.7) 90.1 (87.9, 92.2) 
2 years 84.1 (82.4, 85.8) 63.8 (35.9, 91.7) 78.0 (73.6, 82.5) 89.2 (87.2, 91.2) 
5 years 88.0 (86.2, 89.7)   52.1 (14.9, 89.3) 88.6 (86.8, 90.3) 
10 years 84.6 (81.6, 87.6)     84.2 (81.4, 87.1) 
Note: Overall, HRQOL was not significantly different for oropharyngeal squamous cell carcinoma (OPSCC) patients 
vs non-OPSCC patients. Higher prediagnosis HRQOL quartile was not significantly associated with improved 
survival in 131 OPSCC patients with prediagnosis data (HR, 0.95; p = 0.32). HRQOL recovery to baseline after 
treatment not observed after stratification by survival group. No chemotherapy data and limited surgery data 
available, treatment-related HRQOL changes could not be fully examined. 
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5 
Kent, 2015, ; Oral cavity and pharyngeal cancers;x, US [52]; SF-
6D calculated from SF-36 data; VR-6D calculated from the 
Veterans RAND 12-item Health Survey (VR-12); Data derived 
from the Surveillance Epidemiology and End Results (SEER) 
national cancer registry system linked with the Medicare 
Health Outcomes Survey (MHOS), covering 10 cohorts from 
1998 to 2009. Included patients with oral cavity and 
pharyngeal cancers in their primary diagnoses. SF-36 used to 
measure quality of life in the first 6 cohorts, VR-12 used in 
cohorts 7-10; Last author received grants from the NIA and the 
NIMHD.  
Mean SF-6D/VR-6D (95% CI) 0.69 (0.68, 0.70) 
 
6 
Loimu, 2015, ; Head and neck cancer;, Finland [53]; 15D; 
Prospective cohort study of 64 patients with laryngeal, 
pharyngeal or nasal cavity carcinoma treated with definitive 
(chemo) radiotherapy betwee November 2007-July 2012 
completed 15D health-related quality of life (HRQoL) 
questionnaire; HRQoL measured at baseline, 3, 6, 12 months 
after treatment onset. 75% males, mean age 61.6 (range: 40-
81) years; The Helsinki University Central Hospital 
Research Funds. 
  Mean 15D score, all patients, n = 64 
Compared with 15D of standardised Finnish 
general population 
Baseline  0.886 (0.10)  
Difference not statistically significant or in 
clinically important manner 
3 months  0.829 (0.12)    
6 months  0.860 (0.12)    
12 months  0.862 (0.14)  
Difference not statistically significant or in 
clinically important manner 
 
7 
Noel, 2015, ; Head and neck cancer, ; Canada [54]; SG, TTO, 
VAS, EQ-5D-5L, Health Utilities Index Mark 3 (HUI3); Cross-
sectional study of 100 upper aerodigestive tract squamous cell 
carcinoma patients with minimum 3 months follow-up after 
surgery or radiotherapy treatment completion with no 
recurrence or metastatic disease, recruited from 1 August to 
31 October 2014. 75% male, mean age 61 (range 31-92); 
Funding source not specified 
EQ-5D 0.82 (SD: 0.18, range: -0.07-1.0) 
SG 0.91 (SD: 0.17, range: 0.2-1.0) 
TTO 0.94 (SD: 0.14, range: 0.3-1.0) 
VAS 0.76 (SD: 0.19, range: 0.2-1.0) 
HUI3 0.75 (SD: 0.25, range: -0.06-1.0) 
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8 
Pottel, 2015;, Head and neck cancer;, Belgium [55]; EQ-5D, 
Vulnerable Elders Survey-13 (VES-13), Geriatric-8 (G-8) 
questionnaire, and comprehensive geriatric assessment (CGA); 
This was an observational, multicentre, prospective study. 
Head and neck cancer patients aged 65+ years, eligible for 
curative primary or adjuvant radiotherapy, with or without 
concomitant systemic therapy, excluding tumours of the 
parotid gland or nasal cavity and paranasal sinuses, were 
recruited from January 2010 to April 2012. EQ-5D self-
completed or through patient interview at week-0 and week-
4; postal EQ-5D at month-2, 5, 12, 24, and 36 after treatment 
start. EQ-5D index scores followed that developed by 
Cleemput obtained from 548 Flemish (Belgian) respondents; 
the Belgian Federal Government, National Cancer Plan. 
EQ-5D complete for 81 patients 
Post-treatment EQ-5D postal response was 90% 
  General median (Q1, Q3) EQ-5D index score 
Prior to treatment start 0.66 (0.55, 0.76) 
Week-4 (mid-therapy) 0.42 (0.26, 0.73) 
Month-2 (end of 
treatment) 0.66 (0.29, 0.76) 
Month-5 0.66 (0.27, 0.76) 
Month-12 0.64 (0.0, 0.76) 
Month-24 0.29 (0.0, 0.76) 
Month-36 0.0 (0.0, 0.67) 
Vulnerable patients showed significantly lower EQ-5D index scores compared to fit patients, before, during, and 
after treatment start (p<0.05) 
 
9 
Lango-, 2014, ; Head and neck cancer;, US [56]; EQ-5D-3L, 
Swal-QOL; Study recruited 159 patients newly diagnosed head 
and neck squamous cell carcinoma (HNSCC)  with no history of 
prior treatment for head and neck cancer, no evidence of 
distant metastases, and were treated with curative intent. 
Recruitment period was from December 2006 to December 
2012. 80% males, median patient age: 60 (range: 32-85); the 
American Cancer Society. 
Median EQ-5D utility value 85 (IQR: 70-90) 
 
10 
Nijdam, 2008, ; Head and neck cancer;, The Netherlands [57]; 
EQ-5D, performance status scale (PSS) for head and neck 
cancer patients, European Organization for Research and 
Treatment of Cancer (EORTC)-QoL questionnaire (QLQ-C30), 
EORTC Head and Neck (H&N35) module, and VASxero specific 
for xerostomia-related issues; All patients with tumours of the 
tonsillar fossa, soft palate, or base of tongue, and between 2 
to 10 years alive with no evidence of diseases were eligible for 
a quality of life survey conducted in 2003 and again in 2005, 
the latter included EQ-5D questionnaire; Funding source not 
specified. 
  Median value 
EQ5D values, same for both 
brachytherapy group (n = 75) and 
surgery group (n = 44), p=0.87 75 
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11 
Rogers, 2006, ; Head and neck,  cancer; UK [58]; EQ-5D, EQ-
VAS, and University of Washington Quality of Life 
Questionnaire Version 4 (UW-QOL V4); This was a cross-
sectional postal survey conducted in 2004 of patients treated 
for oral/oropharyngeal squamous cell carcinoma by primary 
surgery between 1992 to 2003. EQ-5D utility score calculated 
using UK value set. Mean age 65 (SD: 12); 224 completed 
questionnaires; Funding source not specified 
EQ5D mean utility (health index) 0.75 (SE: 0.02; range: -0.18 to 1.0) 
Overall mean EQ-VAS 74 (SE: 1) 
 
12 
Ringash-, 2000;, Layngeal cancer, ; Canada [59]; TTO, patient 
completed; 114 laryngeal cancer patients treated mainly with 
primary radiotherapy and seen in follow-up between May and 
November 1998 complete TTO utility measure and the 
Functional Assessment of Cancer Therapy Head and Neck 
quetionnaire Version 4 (FACT-H&N). For the TTO, patients 
considered a given period of time in current health state and 
decided what period of time perfect health would be of equal 
value; questionnaired administered via structured personal 
interview; Funding source not specified. 
  Mean (SD; range) 
TTO, n=112 0.914 (0.156; 0.25 to 1) 
TTO, excluding patients who claimed they had or did not want perfect 
health, n=84 
0.878 (0.174; 0.25 to 1) 
 
13 
Downer, 1997, ; Oral cancers;, UK [60]; SG; A convenience 
sample of 100 staff members of a commercial company, 
excluding those with relatives or friends with oral cancer or 
who had medical knowledge of the disease, completed SG 
questionnaire. Three health states descriptions were 
considered, these were oral precancer, early oral cancer, and 
late oral cancer. 62% of respondents were male. Mean age 
49.81 years; Funding source not specified. 
Health state Mean utility value (SD) 
Precancer 0.92 (0.18) 
Stage 1 cancer 0.88 (0.20) 
Stage 2+ cancer 0.68 (0.33) 
 
14 
Marcellusi, 2015, ; AGW, anal, head and neck, Italy; TTO and 
EQ-5D [38]; 465 patients, mean age 44.0 (SD 16.3) years and 
135 controls, mean age 44.0 (SD 13.2) years enrolled over 31 
October  2008 to 31 July 2012; Sanofi Pasteur MSD, Italy and 
partly funded by the Italian Ministry o fEducation, University 
and Scientific Research. 
Patients with Overall n 
Mean EQ-5D utility 
(SD) 
Mean EQ-5D utility 
(SD), males 
Mean EQ-5D utility 
(SD), females 
anal cancer 26 0.6 (0.3) 0.7 (0.2) 0.4 (0.3) 
anal cancer, controls 10 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 
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head and neck squamous cell 
carcinoma 
79 0.8 (0.2) 0.8 (0.2) 0.7 (0.2) 
head and neck squamous cell 
carcinoma, controls 
20 0.9 (0.3) 1 (0.1) 0.8 (0.3) 
Patients with   
Mean TTO utility 
(SD; 95% CI) 
Mean TTO utility 
(SD), males 
Mean TTO utility 
(SD), females 
anal cancer   0.5 (0.26; 0.4-0.61) 0.48 (0.24) 0.54 (0.31) 
anal cancer, controls   
0.52 (0.25; 0.36-
0.67) 
    
head and neck squamous cell 
carcinoma 
  0.69 (0.3; 0.62-0.75) 0.7 (0.32) 0.64 (0.21) 
head and neck squamous cell 
carcinoma, controls 
  0.59 (0.3; 0.46-0.72)     
 
15 
Conway, 2012, ; Anal, oropharyngeal, vaginal, vulvar, penile, 
Australia [61]; SG; 99 general population participants (54% 
male) given SG scenarios of HPV-associated cancer health 
states, focusing on longer term health states, starting after the 
initial treatment effects had resolved to 5 years after 
diagnosis. Since morbidity of longer term health states is 
related to treatment modality, health state descriptions 
considered most common cancer stages at diagnosis, 
recommended treatment for relevant cancer stages, and 
common long-term consequences; Funded by CSL 
Biotherapies, a subsidiary of CSL Limited, which is a financial 
beneficiary of sales of Gardasil and Cervarix; CSL Biotherapies 
distributes Gardasil in Australia and New Zealand. 
Scenario N Mean (95% CI) Median (IQR) 
Anal cancer 95 0.57 (0.52 to 0.62) 0.65 (0.45 to 0.75) 
Oropharyngeal cancer 99 0.58 (0.53 to 0.63) 0.65 (0.45 to 0.75) 
Vaginal cancer 98 0.59 (0.54 to 0.64) 0.65 (0.45 to 0.75) 
Vulvar cancer 98 0.65 (0.60 to 0.70) 0.65 (0.45 to 0.85) 
Penile cancer 97 0.79 (0.74 to 0.84) 0.85 (0.65 to 1.0) 
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